UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM
10-K
x
|
Annual
report pursuant to Section 13 or 15(d) of The Securities Exchange Act of
1934
|
|
For the
fiscal year ended:
December 31,
2009
or
¨
|
Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
|
|
Commission
file number:
0-6511
O.I. CORPORATION
(Exact
name of registrant as specified in its charter)
Oklahoma
|
73-0728053
|
(State
of Incorporation)
|
(IRS
Employer Identification No.)
|
|
|
151
Graham Road, Box 9010
|
|
College
Station, Texas
|
77842-9010
|
(Address
of principal executive offices)
|
(Zip
Code)
|
Registrant's
Telephone Number, including area code: (979) 690-1711
Securities
Registered Pursuant to Section 12(b) of the Act:
Title of each class
|
|
Name of each exchange on which registered
|
Common
Stock, par value $0.10 per share
|
|
NASDAQ
Global
Market
|
Securities
Registered Pursuant to Section 12(g) of the Act: NONE
Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in
Rule 405 of the Securities Act. Yes
¨
No
þ
Indicate
by check mark if the registrant is not required to file reports pursuant to
Section 13 or Section 15(d) of the Exchange Act. Yes
¨
No
þ
Indicate
by check mark whether the registrant (1) has filed all reports required to be
filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the
preceding 12 months (or for such shorter period that the registrant was required
to file such reports), and (2) has been subject to such filing requirements for
the past 90 days. Yes
þ
No
¨
Indicate
by check mark whether the registrant has submitted electronically and posted on
its corporate Website, if any, every Interactive Data File required to be
submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding
12 months (or for such shorter period that the registrant was required to submit
and post such files). Yes
¨
No
¨
Indicate
by check mark if disclosure of delinquent filers pursuant to Item 405 of
Regulation S-K is not contained herein, and will not be contained, to the best
of registrant’s knowledge, in definitive proxy or information statements
incorporated by reference in Part III of this Form 10-K or any amendment to this
Form 10-K.
¨
Indicate
by check mark whether the registrant is a large accelerated filer, an
accelerated filer, a non-accelerated filer or a smaller reporting
company. See definitions of “large accelerated filer,” “accelerated
filer” and “smaller reporting company” in Rule 12b-2 of the Exchange
Act. (check one):
Large
accelerated filer
¨
|
Accelerated
filer
¨
|
Non-accelerated
filer
¨
(Do
not check if a smaller reporting company)
|
Smaller
reporting company
þ
|
Indicate
by check mark whether the registrant is a shell company (as defined in Rule
12b-2 of the Exchange Act). Yes
¨
No
þ
The
aggregate market value, as of June 30, 2009, of the common stock (based on the
average of bid and asked prices of these shares on NASDAQ) of O.I. Corporation
held by non-affiliates (assuming, for this purpose, that all directors, officers
and owners of 5% or more of the registrant's common stock are deemed affiliates)
was approximately $7,289,082.
The
number of outstanding shares of the common stock as of March 3, 2010 was
2,365,111.
DOCUMENTS
INCORPORATED BY REFERENCE
Portions
of the registrant’s Proxy Statement for the 2010 Annual Meeting of
Shareholders
are
incorporated by reference into Part III of this Form 10-K. Except
with respect to the information specifically
incorporated
by reference in this Form 10-K, the Proxy Statement is not deemed to be filed as
a part hereof.
TABLE
OF CONTENTS
|
|
|
Page
|
Cautionary
Statement
|
|
1
|
|
|
|
|
PART
I
|
|
|
Item
1
|
Business
|
|
1
|
Item
1A
|
Risk
Factors
|
|
6
|
Item
1B
|
Unresolved
Staff Comments
|
|
8
|
Item
2
|
Properties
|
|
8
|
Item
3
|
Legal
Proceedings
|
|
8
|
Item
4
|
Reserved
|
|
8
|
|
|
|
|
PART
II
|
|
|
|
|
|
|
Item
5
|
Market
for the Registrant’s Common Equity, Related Stockholder Matters and
Issuer
|
|
|
|
Purchases
of Equity Securities
|
|
9
|
Item
6
|
Selected
Financial Data
|
|
10
|
Item
7
|
Management’s
Discussion and Analysis of Financial Condition and Results of
Operations
|
|
10
|
Item
7A
|
Quantitative
and Qualitative Disclosures About Market Risk
|
|
15
|
Item
8
|
Financial
Statements and Supplementary Data
|
|
15
|
Item
9
|
Changes
in and Disagreements with Accountants on Accounting and Financial
Disclosure
|
|
31
|
Item 9A(T)
|
Controls
and Procedures
|
|
32
|
Item
9B
|
Other
Information
|
|
32
|
|
|
|
|
PART
III
|
|
|
|
|
|
|
Item
10
|
Directors,
Executive Officers and Corporate Governance
|
|
33
|
Item
11
|
Executive
Compensation
|
|
33
|
Item
12
|
Security
Ownership of Certain Beneficial Owners and Management and
Related
|
|
|
|
Stockholder
Matters
|
|
33
|
Item
13
|
Certain
Relationships and Related Transactions, and Director
Independence
|
|
33
|
Item
14
|
Principal
Accounting Fees and Services
|
|
33
|
|
|
|
|
PART
IV
|
|
|
|
|
|
|
Item
15
|
Exhibits
and Financial Statement Schedules
|
|
34
|
This Annual Report on Form 10-K
contains forward-looking statements within the meaning of United States
securities laws, including the United States Private Securities Litigation
Reform Act of 1995. Forward-looking information is often, but not
always identified by the use of words such as “anticipate”, “believe”, “expect”,
“plan”, “intend”, “forecast”, “target”, “project”, “may”, “will”, “should”,
“could”, “estimate”, “predict” or similar words suggesting future outcomes or
language suggesting an outlook. Forward-looking statements in this Annual Report
on Form 10-K include, but are not limited to, statements with respect to
expectations of our prospects, future revenues, earnings, activities and
technical results.
You are cautioned that any such
forward-looking statements are not guarantees of future performance and involve
a number of risks and uncertainties such as: the stability of the economic
markets, technological change which could cause our products to become
non-competitive or obsolete, the success of research and development efforts,
prosecution and defense of our intellectual property, potential parts shortages,
consolidation in the marketplace, changes in environmental regulations, economic
and political factors affecting international sales, and risks associated with
being a microcap public company. Actual results could differ materially from
those indicated by such forward-looking statements. Factors that could cause or
contribute to such differences include those discussed under “Risk Factors” in
this report and in our Quarterly Reports on Form 10-Q. O.I.
Corporation disclaims any intention or obligation to update or revise any
forward-looking statements, whether as a result of new information, future
events or otherwise.
PART
I
Item
1. Business
General
O.I.
Corporation (referred to as “the Company,” “OI,” “we,” “our” or “us,”) provides
innovative products for chemical analysis and monitoring. Our
products perform detection, analysis, measurement and monitoring applications in
a wide variety of industries, including environmental testing, food and flavors,
pharmaceutical, semiconductor, power generation, chemical, petrochemical and
security. We sell our products throughout the world utilizing a
direct sales force as well as a network of independent sales representatives and
distributors. Our primary strategy is to identify market niches we
can penetrate using our product development capabilities, manufacturing
processes and marketing skills with the goal of assuming a market leadership
position. Management continually emphasizes product innovation,
quality improvement, performance enhancement and on-time delivery while striving
for product cost improvements to promote added value for our products. We seek
growth opportunities through: 1) the development of new applications for
existing products, 2) technological and product improvement to develop new
products for both new and existing markets and 3) the acquisition and
development of new products and competencies.
OI was
organized in 1963, in accordance with the Business Corporation Act of the State
of Oklahoma, as Clinical Development Corporation, a builder of medical and
research laboratories. In 1969, we moved our headquarters from
Oklahoma City, Oklahoma, to College Station, Texas, and changed our name to
Oceanography International Corporation. To better reflect current
business operations, we again changed our name to O.I. Corporation in July 1980,
and in January 1989 we began doing business as OI Analytical.
Our
principal executive offices are located at 151 Graham Road, College Station,
Texas, 77842, our telephone number is (979) 690-1711 and our website address is
http://www.oico.com. Our Annual Report on Form 10-K, Quarterly Reports on
Form 10-Q, Current Reports on Form 8-K and amendments to those reports
filed or furnished pursuant to Section 13(a) or 15(d) of the
Securities Exchange Act of 1934 are available through the investor relations
page of our internet website free of charge as soon as reasonably
practicable after we electronically file such material with, or furnish it to,
the Securities and Exchange Commission (the “SEC”). Our internet website and the
information contained therein or connected thereto are not intended to be
incorporated into this Annual Report on Form 10-K. Our common
stock is traded on the NASDAQ Global Market under the symbol
“OICO”.
Operations
We
design, manufacture, sell and service products in two segments: Laboratory
Products and Air Monitoring Systems. The Laboratory Products segment
may be further broken down into the following primary areas: 1) Gas
Chromatograph (or “GC”) Instruments and Systems, 2) Total Organic Carbon
Analyzer (or “TOC”) Systems, 3) Automated Chemistry Analyzers (or “ACA”), and 4)
Other Products. Our products in each of these areas are further
described below.
Laboratory
Products
Gas
Chromatography Instruments and Systems
Gas chromatography is
an analytical technique that separates organic compounds based on their unique
physical and chemical properties. We manufacture Purge and Trap
Sample Concentrators (or “P&T”) used for sample introduction into
GCs. In addition, we manufacture a broad range of specialized GC
detector devices. We also purchase analytical instruments including
GCs and GC mass spectrometers (or “GC/MS”) manufactured by GC
companies. A number of these purchases occur under our Value Added
Reseller (“VAR”) agreement with Agilent Technologies, Inc. We
typically integrate GC components with GCs and GC/MS to configure customized GC
analyzer systems, including volatile organic compound analyzers, sulfur and
pesticide analyzers. These systems are typically used for testing
water to ensure compliance with applicable regulations, such as the US
Environmental Protection Agency (or “EPA”)standards.
Total Organic
Carbon Analyzer Systems
Total Organic Carbon (or “TOC”)
analyzers and related accessories are used to measure organic and inorganic
carbon levels in ultrapure water, drinking water, natural water, groundwater,
wastewater, process waters, soils and solids. Our TOC analyzers can
be employed to comply with methods and testing required by the EPA and other
world-wide regulatory agency requirements; to ensure compliance with
pharmacopoeia testing standards for ultrapure water used in manufacturing
pharmaceuticals; to monitor pure water used in semiconductor manufacturing and
power generation; and to provide data for oceanographic
research. Customers often select TOC products based on the method of
oxidation of a sample. Our TOC analyzers oxidize samples by High
Temperature Persulfate and combustion; the two most widely recognized methods in
the industry. We also produce a TOC Solids Analyzer designed to
analyze samples with very high particulates and solids. The
electrochemical oxidation process we developed for NASA was launched to the
International Space Station in November of 2008. We sold our first
units based on the commercial version of this technology in the fourth quarter
of 2009 and are developing a distribution channel to enhance our ability sell
this product into industries that require on-line, continuous monitoring of
water streams, such as chemical and petro-chemical facilities as well as
drinking and waste water facilities.
Automated
Chemistry Analyzers
Our products in this area include
Segmented Flow Analyzers (or “SFA”) and Flow Injection Analyzers (or “FIA”) such
as the Flow Solution
®
IV, Flow
Solution 3100, and Model DA-3500 Discrete Analyzer. These instruments
perform a wide range of ion analyses, including the measurement of nitrate,
nitrite, phosphate, ammonia, chloride, alkalinity, and sulfate in
liquids. Our CNSolution Analyzer can perform total cyanide analysis
in a number of industrial and environmental applications including cyanide
testing in gold and silver mining, electroplating, metal finishing, and
semiconductor operations.
Other
Products
Sample Preparation Products and
Systems
Our sample preparation instrumentation products
are used to prepare sample matrices for analysis. Sample preparation
typically represents the most time-consuming aspect of chemical
analysis. We strive to provide procedures, techniques, and
instruments to reduce total sample preparation time, a highly desired goal for
our customers in the analysis of chemical compounds. Our sample
preparation products and systems consist primarily of Gel Permeation
Chromatography (or “GPC”) Systems.
Specific Air
Monitors
Specific air monitors employ infrared (or “IR”)
based analyzers to continuously monitor and detect low-level refrigerant
leaks. These monitors are used in the chiller/refrigerant industry to
detect all refrigerants including CFCs (chlorofluorocarbons), HFCs
(hydrofluorocarbons), and HCFCs (hydrochloro-fluorocarbons). In
addition, these monitors can be utilized to detect carbon monoxide gas in
parking garage applications.
Air-Monitoring
Systems
For
continuous air-monitoring applications, we produce our MINICAMS
â
product line of configured GC systems in standard and custom configurations to
meet customers’ needs in the field. Our customers use MINICAMS to
monitor air for toxic chemical compounds including gaseous chemical-warfare
agents such as mustard, sarin, Lewisite, and others to address air-monitoring
levels as promulgated by the Centers for Disease Control and
Prevention.
Sales
by Location
We
generally transact all sales in U.S. Dollars. Estimated net revenues
attributable to the United States, export revenues as a group, and the number of
countries in which export revenues were generated, are as follows:
$ in thousands
|
|
2009
|
|
|
2008
|
|
Net
revenues:
|
|
|
|
|
|
|
United
States
|
|
$
|
13,079
|
|
|
$
|
20,349
|
|
Export
|
|
|
6,833
|
|
|
|
8,620
|
|
Total
|
|
$
|
19,912
|
|
|
$
|
28,969
|
|
|
|
|
|
|
|
|
|
|
%
Net revenues:
|
|
|
|
|
|
|
|
|
United
States
|
|
|
66
|
%
|
|
|
70
|
%
|
Export
|
|
|
34
|
|
|
|
30
|
|
Total
|
|
|
100
|
%
|
|
|
100
|
%
|
|
|
|
|
|
|
|
|
|
Number
of countries-export
|
|
|
58
|
|
|
|
49
|
|
The
following regions had sales in excess of 10% of net revenues: sales to the
Asia-Pacific region were approximately 17% of net revenues in 2009 and 12% for
2008, and sales to the European region were approximately 14% of net revenues
for both 2009 and 2008.
For
additional financial information, including financial information for the last
two years on total assets, please see Item 8 “Financial Statements and
Supplementary Data” and the notes to the consolidated financial statements
included in this annual report.
Manufacturing
We
manufacture products in ISO 9001 certified facilities located in College
Station, Texas, and Pelham, Alabama, a suburb of Birmingham, using similar
techniques and methods at both locations. Our manufacturing
capabilities include electro-mechanical assembly, testing and integration of
components and systems, as well as calibration and validation of configured
systems. Our products are generally certified pursuant to safety
standards established by the European Committee for Electrotechnical
Standardization (CE), and/or the Canadian Standards Association
(CSA). These agencies and others certify compliance with certain
manufacturing standards.
Sales
and Marketing
We
market, sell, and support analytical components and systems. In
addition, we provide on-site installation and support services, distribute
consumables, and provide accessories required to support the operation of our
products in the field. Domestically, we sell our products to end
users through a direct sales channel, manufacturers’ representatives, and
resellers; while internationally we primarily sell through
distributors. Our marketing initiatives include advertising, direct
mail, seminars, trade shows, telemarketing, and promotion on our internet web
site at
www.oico.com
.
Technical
Support
We employ
a technical support staff that provides on-site installation, service and
after-sale support of our products with a goal of maximizing customer
satisfaction. We also offer training courses and publish technical
bulletins that contain product repair information, parts lists, and application
support information for customers. Our products generally include a
warranty ranging from ninety days to one year. Customers may also
purchase extended warranties or service contracts that provide coverage after
the expiration of the initial warranty. We install and service
products using our field service personnel or third party contractors in North
America while utilizing distributors with factory certified service personnel in
international locations.
Research
and Development
The
analytical instrumentation industry is subject to rapid changes in
technology. Our future success relies heavily on continued product
enhancement. To accomplish this objective, we seek to advance and
broaden employed technologies, improve product reliability, boost product
performance, augment analytical data handling, reduce product size, and cut
analytical cycle time while maintaining or reducing product cost. In
addition, we actively pursue development of potential new
products. Our efforts to enhance existing products and develop new
products require an extensive investment in research and
development. We expense research and development costs relating to
both present and potential future products as incurred. These
expenses totaled $2,985,000 during 2009 and $3,851,000 during 2008.
Patents
We have a
dynamic portfolio of intellectual property, including both domestic and
international patents and patent applications pending, primarily in the fields
of gas chromatography, TOC, and mass spectrometry or “MS”. As of
December 31, 2009, we own or have rights under license to 44 issued patents and
25 pending patent applications which expire between the years 2010 and 2026,
compared to 41 issued patents in the prior year. As a matter of
policy, we vigorously pursue and protect our proprietary technology positions
and seek patent coverage on technology developments where
appropriate. We also actively seek to license technology in fields of
interest from third parties, provided such licenses are available on reasonable
terms. While we believe that all of our patents and applications have
value, our future success is not dependent on any single patent, application or
group of patents soon to expire.
Competition
We
encounter aggressive competition in all aspects of our business
activity. OI competes with many firms in the design, manufacture, and
sale of analytical instruments, principally on the basis of product technology,
performance, quality, and reliability as well as product support, delivery, and
price. Additional competitive factors include sales and marketing
capability and access to channels of distribution. In OI’s major
product lines, our primary competitors include, but are not limited to: EST
Analytical, Lachat Instruments, Seal Analytical, Shimadzu Scientific
Instruments, Teledyne Tekmar, and Westco Scientific Instruments. Many
of our competitors have significantly greater resources than OI, thereby
offering greater global market coverage, more extensive product offerings,
broader access to human and technical resources, greater buying power with
suppliers, superior brand recognition, larger market share, and greater
financial resources. Our past success in niche market penetration is
not necessarily an indication of future results.
Employees
As of
December 31, 2009, our workforce consisted of 126 full-time
employees. To protect our proprietary information, we generally have
confidentiality agreements in place with employees. None of our
employees are covered by a collective bargaining agreement. We
believe that relations between management and our employees are
satisfactory.
Environmental
Regulations
To the
best of our knowledge, we are in compliance with federal, state, and local laws
and regulations involving the protection of the environment. In the
normal course of business, we often handle small quantities of materials that
could be deemed hazardous. However, hazardous materials are primarily
introduced into our products by end users rather than by OI
employees. Our compliance with federal, state, or local provisions
regulating the discharge of materials into the environment or relating to the
protection of the environment should have no material effect upon planned
capital expenditures, future earnings, or competitive
position. However, to the extent that customers purchase our
analytical instruments for environmental analysis to assist in their compliance
with environmental regulations, changes to these regulations could affect demand
for certain of our products.
Sources
of Raw Materials
We
manufacture our products from raw materials, component parts and other supplies
generally available from a number of different sources with few long-term
supplier contracts. For certain purchased materials, we utilize
preferred sources established on the basis of quality and
service. Single source suppliers provide several purchased
components. We can provide no assurance that these preferred or
single source suppliers will continue to make materials available in sufficient
quantities, at prices and on other terms and conditions that are adequate for
our needs. However, we have no indication that any of these preferred
or single source suppliers will cease to do business with us. Should
we experience a cessation in our relationship with a preferred or single source
supplier, we believe adequate alternate sources can be located without a
material disruption to our customers, though at potentially increased
cost. We use sub-contractors to manufacture certain product
components. In some cases, these sub-contractors are small businesses
that can be materially affected by national as well as local economic conditions
and other business factors that could impact their ability to be reliable
suppliers. Substitute suppliers and/or components may require
reconfiguration of products, which might result in significant product changes
in the view of customers and could ultimately result in our discontinuing such
products.
Backlog
of Open Orders
Our
backlog of orders on December 31, 2009 was approximately $7,442,000, compared to
$1,909,000 in 2008. This $5,533,000 increase in our backlog was
primarily attributable to the $5,680,000 contract with Bechtel National, Inc.
for the purchase of Minicams
®
as
announced on August 28, 2009. We generally include in the backlog
only purchase orders or production releases that have firm delivery dates in the
twelve-month period following our fiscal year-end. However, recorded
backlog may not result in sales because of purchase order changes,
cancellations, or other factors. We anticipate that approximately 75%
of our present backlog of orders will be shipped or completed during 2010 with
the remaining 25% related to the Bechtel order scheduled to ship in the first
half of 2011.
Seasonality
Demand
for our products has not historically exhibited significant seasonal variation
with regard to our consolidated net revenues. However, environmental
markets tend to be weaker in the first and fourth quarters of the calendar year
while U.S. Federal governmental markets are often slightly stronger in the third
quarter of the calendar year.
Customers
Our
customers include environmental testing laboratories, various military agencies
of the U.S. Government, industrial businesses, semiconductor manufacturers,
engineering and consulting firms, municipalities, and chiller-refrigerant
companies. Sales to the U.S. Government accounted for approximately
24% of revenues in 2009 and 21% of revenues in 2008. A decrease in
sales to the U.S. Government could have a material adverse impact on our results
of operations. International sales accounted for approximately 34% of
revenues in 2009 and 30% in 2008.
Item
1A. Risk Factors
Current
economic conditions may adversely affect our business and we do not expect these
conditions to improve in the near future.
Our
business is materially affected by conditions in the global
economy. The capital and credit markets worldwide have experienced
extreme volatility and disruption. Though conditions appear to be
improving, we cannot predict how long this economic downturn may
last. Because of current economic conditions, capital expenditures,
such as purchases of analytical instrumentation, continue to be delayed in many
cases. We cannot predict when consumer confidence in the economy may
increase and when customers may resume purchases of capital equipment at normal
levels. If economic conditions worsen, we may experience a further
decrease in demand for our goods and services. In addition, some of
our customers may have difficulty obtaining access to sufficient credit, which
could impair their ability to make timely payments to us. Some of our
suppliers may also face issues gaining access to sufficient credit to maintain
their business which could reduce the availability of some components we
incorporate in our products. To the extent such suppliers are single
source suppliers, our ability to continue to manufacture and sell our products
could be affected.
Technological
change could cause our products to become non-competitive or
obsolete.
The
market for our products and services is characterized by rapid and significant
technological change and quickly evolving industry standards. New
product introductions responsive to these factors require significant planning,
design, development, and testing. We can provide no assurance that
our products will remain competitive in this rapidly changing
environment. In addition, industry acceptance of new technologies we
seek to introduce may be slow to develop.
We could incur
substantial costs in protecting and defending our intellectual property and loss
of patent rights could have a material adverse effect on our
business
.
We hold
patents relating to various aspects of our products and believe that proprietary
technical know-how is critical to many of our products. Proprietary
rights relating to our products are protected from unauthorized use by third
parties only to the extent that they are covered by valid and enforceable
patents or are maintained in confidence as trade secrets. There can
be no assurance that patents will issue from any pending or future patent
applications owned by or licensed to us or that the claims allowed under any
issued patents will be sufficiently broad to protect our
technology. In the absence of patent protection, we may be vulnerable
to competitors who attempt to copy our products or gain access to our trade
secrets and technical know-how. Our competitors could also initiate
litigation to challenge the validity of our patents or may use their resources
to design comparable products that do not infringe upon our
patents. We could incur substantial costs in defending OI in suits
brought against us or in suits in which we may assert our patent rights against
others. If the outcome of any such litigation is unfavorable to us,
our business and results of operations could be materially and adversely
affected. In addition, we rely on trade secrets and proprietary
technical know-how that we seek to protect, in part, by confidentiality
agreements with our collaborators, employees, and consultants. We can
provide no assurance that these agreements will not be breached, that we would
have adequate remedies for any breach, or that our trade secrets will not
otherwise become known or be independently developed by
competitors.
Our extensive
R&D efforts may not result in products that are successful in the
marketplace.
To
maintain our market share for existing products and to gain market share in new
markets such as homeland security, we must invest heavily each year in R&D
spending. This R&D spending often involves new technologies or
updates to existing technology. We can provide no assurance that our
R&D efforts to develop new technology or efforts to acquire new technology
from third parties will be successful or that new products we may develop
through such efforts will be successful in the marketplace.
Consolidation in
the environmental instrument market and changes in environmental regulations
could adversely affect our business.
Environmental
analysis, which represents a significant market for our products, has exhibited
a trend of contraction and consolidation in recent
years. Continuation of this trend could have an adverse impact on our
business. In addition, most air, water and soil analyses are
conducted to comply with federal, state, local, and foreign environmental
regulations. These regulations are frequently specific as to the type
of technology required for a particular analysis and the level of detection
required for that analysis. We develop, configure, and market our
products to meet customer needs created by existing and expected environmental
regulations. These regulations may be amended or eliminated in
response to new scientific evidence or political or economic
considerations. Any significant change in environmental regulations
could result in a reduction in demand for our products.
Our results of operations are
dependent on our relationship with A
gilent
.
We
currently operate under a Value Added Reseller (or “VAR”) agreement with
Agilent, which was renewed at the end of 2009. Our VAR agreement
provides for certain sales and marketing cooperation between us and
Agilent. We can provide no assurance that Agilent will renew our VAR
agreement, which is renewable annually in December, or that we will sustain
current sales levels or increase sales levels in the future under the Agilent
VAR agreement. A cessation of our relationship with Agilent would
place at risk a substantial part of our GC systems sales and could have a
material adverse effect on our financial condition and results of
operations.
Economic,
political and other risks associated with international sales could adversely
affect our results of operations.
Sales
outside the U.S. accounted for approximately 34% of our revenues in
2009. We expect international sales to account for a significant
portion of our future revenues. Sales to international customers are
subject to a number of risks including interruption to transportation flows for
delivery of finished goods to customers; changes in foreign currency exchange
rates; changes in political or economic conditions in a specific country or
region; trade protection measures and import or export licensing requirements;
negative consequences from changes in tax laws; differing protection of
intellectual property; and unexpected changes in regulatory
requirements. Unfavorable developments in these areas could have a
material adverse effect on our business, results of operations, and financial
position.
Parts shortages
or excess parts inventory could adversely affect our
earnings.
We rely
on various component parts to meet production demands. Should we
encounter a shortage due to loss of a single source supplier or group of
suppliers, for example, we may suffer a loss in sales, which could detrimentally
impact our earnings. In certain cases, we enter into non-cancelable
purchase commitments with vendors to secure components at the best available
price. Should market demand for our products decline unexpectedly, we
may develop excess parts inventory which could result in inventory write-downs
that would negatively impact our results of operations and financial
position.
We
are a small organization and we face many risks inherent in operating a microcap
public company.
Because
we are a relatively small organization, we have limited resources both in terms
of our physical facilities and human resources. Should we suffer a
catastrophic loss in either of our primary facilities, we could face a
significant disruption in our business. To be successful, we rely on
the performance of our employees including key executives such as our CEO/CFO
who serves in a dual capacity, sales and marketing professionals, technical
staff, managers, and production personnel. In addition, we have a
small accounting and finance group charged with the responsibility of public
reporting issues and the increasingly complex requirements of generally accepted
accounting principles in the United States in addition to normal day to day
accounting operations. Our ability to meet customer demand could be
negatively impacted if we are unable to attract, hire, train, retain, and
motivate qualified employees.
As a
small company, the cost of compliance with governmental regulations, including
the Sarbanes-Oxley Act of 2002, or SOX, continues to escalate and represents a
significant expenditure of funds.
We are
considered a microcap company and have a relatively small number of shares of
common stock outstanding, with insiders and holders of 5% or more shares owning
a significant portion of our stock. Because of this concentration of
ownership, our common stock is thinly traded and experiences some periods with
no transactions. This lack of public float adversely affects the liquidity of an
investment in our shares.
We are a
small company with a strong financial position and innovative new
technologies. Our small size could make us the target of a takeover
attempt by a larger company, the defense of which could cause us to incur
significant legal and advisory fees and could serve as a distraction to our
regular business.
Investments
we pursue may be subject to a high risk of loss.
We plan
to evaluate alternative investment options for excess funds to improve our
returns. These investments may include less than investment grade bonds or
other securities that we feel are likely to increase in value and/or provide a
higher interest return. Any such investments are likely to subject us to a
higher risk of loss than our current insured or government backed
investments.
Potential
acquisitions, strategic alliances, joint ventures and divestitures could result
in financial results that do not meet expectations.
We plan
to consider a growth strategy that could potentially include strategic
alliances, joint ventures, or acquisitions. Certain business
acquisitions and strategic alliances in past years have not produced
profitability meeting our expectations. Businesses we may seek to
acquire in the future may also fall short of our profit
objectives. To finance potential acquisitions, we may need to raise
additional funds either through public or private financing. We may
have difficulty in obtaining debt financing on terms we find attractive, while
equity financing can result in significant dilution to our
shareholders.
Should we
complete such a transaction, our financial results may differ from the
investment community’s expectations. We could potentially experience
difficulty developing, manufacturing, and marketing the products of a newly
acquired company in a way that enhances performance of the combined businesses
or product lines to realize the value from expected
synergies. Depending on the size and complexity of an acquisition,
our successful integration of the entity depends on a variety of factors
including: retention of key employees; management of facilities and
employees in separate geographic areas; retention of key customers; and the
integration or coordination of different research and development, product
manufacturing, sales programs, and facilities. All of these efforts
require varying levels of management resources that may divert our attention
from other business operations. If we do not realize the expected
benefits or synergies of such transactions, our consolidated financial position,
results of operations and stock price could be negatively impacted.
Item
1B. Unresolved Staff Comments
None.
Item
2. Properties
We own a
facility with space of approximately 68,650 sq. ft. located on 10.86 acres of
land in College Station, Texas, and have good title, free of any
encumbrances. We lease approximately 20,000 sq. ft. of office,
engineering, laboratory, production, and warehouse space in Pelham, Alabama, a
suburb of Birmingham, under a lease expiring at the end of November 2010 with an
option to extend for one additional one-year renewal period. We also
lease 500 sq. ft. of office space in Edgewood, Maryland, renewable annually in
April with an option to extend for two more one-year renewal
periods. We believe that the facilities we occupy are in good
condition and are suitable for our present operations and that additional space
is readily available for expansion or to accommodate our operations should any
of our leases not be extended.
Item
3. Legal Proceedings
We are
not subject to any material legal proceedings. From time to time, in
the ordinary course of business, we have received, and in the future may
receive, notice of claims against us, which in some instances have developed, or
may develop, into lawsuits. For all claims, in the opinion of our
management, based upon presently available information, either adequate
provision for anticipated costs has been made by insurance, accruals or
otherwise, or the ultimate anticipated costs resulting will not materially
affect our consolidated financial position, results of operations, or cash
flows.
Item
4. Reserved
PART
II
Item
5. Market for the Registrant’s Common Equity, Related Stockholder
Matters and Issuer Purchases of Equity Securities
Common Stock Market
Information
Our common stock trades on the NASDAQ
Global Market under the symbol “OICO.” The ranges of high and low
trade prices per share of our common stock for each quarterly period during
fiscal 2009 and 2008 were as follows:
|
|
2009
|
|
|
2008
|
|
|
|
High
|
|
|
Low
|
|
|
High
|
|
|
Low
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
First
Quarter
|
|
$
|
10.77
|
|
|
$
|
6.65
|
|
|
$
|
13.95
|
|
|
$
|
9.42
|
|
Second
Quarter
|
|
|
8.25
|
|
|
|
5.20
|
|
|
|
12.65
|
|
|
|
10.27
|
|
Third
Quarter
|
|
|
7.84
|
|
|
|
4.57
|
|
|
|
12.40
|
|
|
|
10.13
|
|
Fourth
Quarter
|
|
|
8.81
|
|
|
|
6.55
|
|
|
|
13.27
|
|
|
|
7.17
|
|
NOTE:
|
The
above quotations represent prices between dealers, do not include retail
markup, markdown, or commission and may not necessarily represent actual
transactions.
|
Number of Holders
of Common Stock
As of March 3, 2010 there were 511
holders of record of OI common stock.
Dividends
During
2006, our Board of Directors established an annual cash dividend of $0.20 per
share, payable $0.05 per quarter. We have continued this dividend
policy through 2009. The payment of future cash dividends under the
policy is subject to the continuing determination by the Board of Directors that
this policy remains in the best interest of shareholders, complies with the law
and does not violate any applicable agreements into which we may
enter. We may discontinue our dividend policy at any
time.
In 2008
and 2009 we declared cash dividends on shares of our common stock in the amount
of:
|
|
Quarters Ended (per share)
|
|
|
|
March 31
|
|
|
June 30
|
|
|
September 30
|
|
|
December 31
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2009
|
|
|
0.05
|
|
|
|
0.05
|
|
|
|
0.05
|
|
|
|
0.05
|
|
2008
|
|
|
0.05
|
|
|
|
0.05
|
|
|
|
0.05
|
|
|
|
0.05
|
|
We paid a
cash dividend of $0.05 per share of common stock in the first quarter of 2010
and anticipate paying a dividend in each quarter of 2010.
Issuer
Repurchases of Equity Securities
There
were no purchases of equity securities that are registered by us pursuant to
section 12 of the Exchange Act during the quarter ended December 31,
2009.
Through
four separate authorizations in May, June, August and October 2008, the Board of
Directors authorized a plan to repurchase up to an additional 265,000 shares of
OI common stock with no specified expiration date. As of December 31,
2009, we may purchase up to an additional 36,007 shares pursuant to this
plan.
Item 6. Selected
Financial Data
Not
Applicable
Item
7. Management’s Discussion and Analysis of Financial Condition and
Results of Operations
Contents
This item
of the annual report on Form 10-K is divided into the following
sections:
|
·
|
Executive
Summary – Provides a brief overview of the year’s results and known
uncertainties that management expects to have an effect on future
results.
|
|
·
|
Results
of Operations – Analyzes our financial results comparing sales, operating
margins, and expenses to prior periods including our expectations of the
effect of trends and uncertainties on future
results.
|
|
·
|
Liquidity
and Capital Resources – Analyzes our cash flow from operating, investing,
and financing activities and further discusses current and projected
liquidity.
|
|
·
|
Critical
Accounting Estimates – Discusses the most significant accounting estimates
that we believe are essential to aid in understanding our reported
financial results.
|
|
·
|
Inflation
– Reviews the impact of inflation on reported
results.
|
Executive
Summary
We
provide innovative products for chemical analysis and monitoring. Our
products perform detection, analysis, measurement, and monitoring applications
in a wide variety of industries including environmental testing, food,
pharmaceutical, semiconductor, power generation, chemical, petrochemical, and
security. Headquartered in College Station, Texas, we sell our
products throughout the world utilizing a direct sales force as well as a
network of independent sales representatives and distributors. Our
primary strategy is to identify market niches we can penetrate using our product
development capabilities, manufacturing processes and marketing skills with the
goal of assuming a market leadership position. Management continually
emphasizes product innovation, quality improvement, performance enhancement, and
on-time delivery while striving for product cost improvements to promote added
value for our products.
2009 was
a difficult and challenging year for OI, as it was for most capital equipment
manufacturers. During the first quarter, we experienced an abrupt
decline in customer orders and generated an operating loss. In
response to this slowdown in business activity, we implemented a number of
cost-savings measures including a 20% reduction in staff at our headquarters
facilities, reductions in pay, elimination of certain employee benefits, reduced
Board-related expenses, and reductions in travel-related expenses.
As a
result of these cost-saving measures, we reduced our 2009 combined SG&A and
R&D expenses by $2,930,000 compared to the previous year. After
our loss in the first quarter, we essentially broke even in the second quarter,
returning to profitability over the balance of the year as sales began to
recover in our lab products segment and we benefitted from our reduced cost
structure.
Despite
the economic downturn, we generated positive cash flow in 2009 while continuing
to pay our normal dividend to shareholders. We ended the year with
$4,614,000 in cash and investments, up $1,180,000 from 2008, and with no bank
debt.
During
the third quarter of 2009, we entered into a $5.7 million contract to provide
MINICAMS
®
systems
to Bechtel National, Inc. for installation at the Pueblo Chemical
Agent-Destruction Pilot Plant currently under construction in Pueblo,
Colorado. We anticipate that shipments under this contract will
significantly impact our 2010 operations in the Air-Monitoring segment and
positively impact our overall earnings.
In 2009
we made substantial progress on several innovative new products that we believe
will improve future revenue growth. These products include our new
Model 9210 Process TOC Analyzers and the iTOC-CRDS Isotopic Carbon Analyzer
that we developed in conjunction with Picarro, Inc. We received our
first orders for the iTOC-CRDS and Process TOC Analyzer in the fourth quarter of
2009 and are working to expand our distribution network for these new
products.
In
addition, we now have a production-ready version of the Ion-Camera
TM
Mass
Spectrometer. We plan to carefully evaluate the market opportunities
for this new product as well as the cost of planned development efforts in the
months ahead in order to properly align our cash flow and revenue enhancement
objectives.
Going
forward, our primary emphasis will be on maximizing free cash flow and return on
invested capital. Our goal is to increase shareholder value by
focusing on capital allocation. With our lower cost structure, we
feel we are well positioned to leverage improved profitability from our
Laboratory Products segment should economic conditions continue to show
improvement. We also expect improved results from our Air-Monitoring
segment as we make shipments under the Bechtel contract noted
above.
Results
of Operations
Sales by Segment $(000)
|
|
2009
|
|
|
2008
|
|
|
$ Change
|
|
|
% Change
|
|
Laboratory
Products
|
|
|
14,883
|
|
|
|
21,836
|
|
|
|
(6,953
|
)
|
|
|
-31.8
|
%
|
Air-Monitoring
Systems
|
|
|
5,029
|
|
|
|
7,133
|
|
|
|
(2,104
|
)
|
|
|
-29.5
|
%
|
Total
|
|
|
19,912
|
|
|
|
28,969
|
|
|
|
(9,057
|
)
|
|
|
-31.3
|
%
|
Net
Revenues.
Total net revenues for the
year ended December 31, 2009 decreased $9,057,000, or 31.3%, compared to
2008. Sales in both the Laboratory Products and the Air-Monitoring
Systems segments declined approximately 30% compared to 2008 due primarily to
the global economic downturn.
In the
Laboratory Products segment, 2009 sales decreased 31.8% compared to
2008. Domestic sales were hardest hit by the economic downturn and
declined 40% compared to 2008, while international sales were down 21% over the
same period. Our international sales decline was largely attributable
to Europe which had a 31% decrease and Latin America which had a 42%
decrease. Asian sales were virtually unchanged compared to 2008 as
the economic downturn had less of an impact in this region and our reorganized
sales force began to have an impact. From a product line standpoint,
our ACA product line and GC detector product line experienced the smallest
decline in sales, while GC Systems had the largest decrease as customers delayed
major purchases. Our other product lines declined at essentially the
same rate as overall sales.
Service
revenue decreased $341,000, or 10%, during 2009 in comparison to
2008. This decrease resulted from decreased billings under our
contract with the U.S. Army. During 2007, we were awarded a contract
extending through 2009 from the U.S. Army to further refine the technology
initially developed under the Wyle contract in 2006. Revenues under
the Army contract declined in the second half of 2009 as we neared
completion.
The
overall economy appears to be improving, and we anticipate slowly increasing
sales during 2010 in the Laboratory Products segment based on sales of new
products and the improving economy. In the Air-Monitoring Systems
segment, we anticipate significantly improved sales due to shipments under the
Bechtel contract which should begin in the first quarter of 2010.
Gross Profit by Segment $(000)
|
|
2009
|
|
|
% of Sales
|
|
|
2008
|
|
|
% of Sales
|
|
|
$ Change
|
|
Laboratory
Products
|
|
|
6,750
|
|
|
|
45.4
|
%
|
|
|
10,030
|
|
|
|
45.9
|
%
|
|
|
(3,280
|
)
|
Air-Monitoring
Systems
|
|
|
3,022
|
|
|
|
60.1
|
%
|
|
|
4,237
|
|
|
|
59.4
|
%
|
|
|
(1,215
|
)
|
Total
|
|
|
9,772
|
|
|
|
49.1
|
%
|
|
|
14,267
|
|
|
|
49.2
|
%
|
|
|
(4,495
|
)
|
Gross
Profit.
Our gross profit margin decreased $4,495,000 in 2009
compared to 2008 because of lower sales. However, as a percentage of
sales, our margins were virtually unchanged as reduced warranty costs offset the
impact of higher unfavorable variances associated with lower production and
sales of lower margin systems orders were disproportionately impacted by the
economy. We anticipate continued pressure on margins, particularly in
the Laboratory Products segment, during 2010 due to aggressive
competition.
SG&A Expenses by Segment $(000)
|
|
2009
|
|
|
% of Sales
|
|
|
2008
|
|
|
% of Sales
|
|
|
$ Change
|
|
Laboratory
Products
|
|
|
5,120
|
|
|
|
34.4
|
%
|
|
|
6,697
|
|
|
|
30.7
|
%
|
|
|
(1,577
|
)
|
Air-Monitoring
Systems
|
|
|
1,772
|
|
|
|
35.2
|
%
|
|
|
2,259
|
|
|
|
31.7
|
%
|
|
|
(487
|
)
|
Total
|
|
|
6,892
|
|
|
|
34.6
|
%
|
|
|
8,956
|
|
|
|
30.9
|
%
|
|
|
(2,064
|
)
|
Selling, General
and Administrative, (or “SG&A”) Expenses.
SG&A
expenses for 2009 decreased $2,064,000, or 23%, compared to 2008. Our
2009 SG&A expenses declined due to the cost reduction measures taken during
the first half of 2009 as noted above. Despite our significant
reduction in SG&A expenses, as a percentage of sales SG&A expenses
increased to 34.6% in 2009, compared to 30.9% in 2008 because of lower
revenues. We will continue to evaluate cost control measures going
forward in order to maintain and improve profitability.
R&D Expenses by Segment $(000)
|
|
2009
|
|
|
% of Sales
|
|
|
2008
|
|
|
% of Sales
|
|
|
$ Change
|
|
Laboratory
Products
|
|
|
1,578
|
|
|
|
10.6
|
%
|
|
|
2,126
|
|
|
|
9.7
|
%
|
|
|
(548
|
)
|
Air-Monitoring
Systems
|
|
|
1,407
|
|
|
|
28.0
|
%
|
|
|
1,725
|
|
|
|
24.2
|
%
|
|
|
(318
|
)
|
Total
|
|
|
2,985
|
|
|
|
15.0
|
%
|
|
|
3,851
|
|
|
|
13.3
|
%
|
|
|
(866
|
)
|
Research and
Development Expenses
. R&D expenses decreased $866,000
during 2009, or 22%, compared to 2008. The decrease in R&D
expenses was primarily attributable to the cost reduction measures taken during
the first half of 2009. Though down significantly in 2009, R&D
expenses increased to 15.0% of revenues for 2009 compared to 13.3% of revenues
in 2008 due to lower revenues.
Operating Income(Loss) by Segment $(000)
|
|
2009
|
|
|
% of Sales
|
|
|
2008
|
|
|
% of Sales
|
|
|
$ Change
|
|
Laboratory
Products
|
|
|
52
|
|
|
|
0.3
|
%
|
|
|
1,207
|
|
|
|
5.5
|
%
|
|
|
(1,155
|
)
|
Air-Monitoring
Systems
|
|
|
(157
|
)
|
|
|
-3.1
|
%
|
|
|
253
|
|
|
|
3.5
|
%
|
|
|
(410
|
)
|
Total
|
|
|
(105
|
)
|
|
|
-0.5
|
%
|
|
|
1,460
|
|
|
|
5.0
|
%
|
|
|
(1,565
|
)
|
Operating
Income/(Loss).
Because of our lower
revenues, we generated a consolidated operating loss of $105,000
in 2009 despite the large
reductions in SG&A and R&D expenses in both operating
segments. Although our cost savings efforts in the first half of the
year resulted in a slight profit in the Laboratory Products segment, the
Air-Monitoring segment generated an operating loss because of lower sales
volume.
Interest Income
and Other Income/(Loss).
In 2009, non-operating income totaled
$49,000 compared to a non-operating loss of $464,000 in 2008. In 2009
all of our funds were in cash and money market accounts that are paying
historically low interest rates. In 2008 we recognized losses when we
liquidated our preferred stock holdings during the second and third quarters of
the year. Our total loss recognized on the sale of investments in
2008 was $713,000. These losses were partially offset by dividend and
interest income. We anticipate low interest income in 2010 because of
continued low interest rates.
Provision For
Income Taxes.
The current year’s tax
benefit was $110,662 as compared to the expected statutory federal and state
benefit of approximately $22,000. The increase was as a result of an
estimated $150,000 research and development credit and the reversal of a portion
of our valuation allowance on utilized capital loss carry forwards of
$43,000. These benefits were somewhat offset by permanent tax
differences primarily relating to nondeductible stock based
compensation. We expect our effective tax rate to return to a more
normal level in 2010.
Effective
January 1, 2007, we adopted the provisions of FIN 48 and established certain
unrecognized tax benefits related to uncertain tax positions. As of
September 30, 2008, we were no longer subject to U.S. Federal income tax
examination on a portion of these uncertain tax positions and accordingly
recorded a tax benefit of $285,000 during the third quarter of
2008. Because of the impact of this tax benefit, as well as certain
permanent differences between our book and taxable income that reduce our tax
liability, our effective tax rate for 2008 totaled (2.4)%.
Liquidity
and Capital Resources
We
consider a number of liquidity and working capital performance ratios in
evaluating our financial condition. The following table includes
certain ratios, working capital information, and summarized cash flows for use
in understanding our current liquidity and recent trends in this
area:
($
in thousands)
|
|
2009
|
|
|
2008
|
|
|
|
|
|
|
|
|
Liquidity
and Working Capital Performance Measures
|
|
|
|
|
|
|
|
|
Ratio
of current assets to current liabilities
|
|
|
5.7
|
|
|
|
4.6
|
|
Total
liabilities to equity
|
|
|
16
|
%
|
|
|
20
|
%
|
Working
capital
|
|
$
|
13,601
|
|
|
$
|
13,294
|
|
Cash,
cash equivalents and investments
|
|
$
|
4,614
|
|
|
$
|
3,434
|
|
|
|
|
|
|
|
|
|
|
Changes
in Cash and Cash Equivalents
|
|
|
|
|
|
|
|
|
|
|
Net
cash provided by (used in):
|
|
|
|
|
|
|
|
|
Operating
activities
|
|
$
|
1,765
|
|
|
$
|
1,331
|
|
Investing
activities
|
|
|
104
|
|
|
|
1,959
|
|
Financing
activities
|
|
|
(389
|
)
|
|
|
(3,512
|
)
|
|
|
|
|
|
|
|
|
|
Net
increase (decrease) in:
|
|
|
|
|
|
|
|
|
Cash
and cash equivalents
|
|
|
1,480
|
|
|
|
(222
|
)
|
|
|
|
|
|
|
|
|
|
Cash
and cash equivalents:
|
|
|
|
|
|
|
|
|
Beginning
of year
|
|
|
3,134
|
|
|
|
3,356
|
|
End
of year
|
|
|
4,614
|
|
|
|
3,134
|
|
Cash
provided by operating activities during 2009 totaled $1,765,000, compared to
1,331,000 in 2008. Net income decreased $965,000 in
2009. However, this reduction was more than offset by decreased
accounts receivables, which resulted from improved collections and lower sales
activity. Our cash provided by operating activities was also
favorably impacted by decreased in inventory and lower investment in sales type
leases partially offset by an increase in other
payables.
Cash
provided by investing activities totaled $104,000 in 2009, compared to
$1,959,000 in 2008. In 2009 we liquidated $300,000 of investments
compared to $2,326,000 in 2008 when we liquidated certain investments to reduce
risk and fund stock repurchases. During 2009 we limited capital
expenditures to conserve cash. As a result, purchases of property,
plant and equipment totaled $160,000 in 2009 compared to $348,000 in
2008. We had no material commitments for the purchase of property,
plant and equipment outstanding as of December 31, 2009 and have no major
planned commitments for 2010.
Cash used
in financing activities totaled $389,000 in 2009 compared to $3,512,000 in
2008. During 2009 we repurchased 1,000 shares of OI common stock
compared to 284,569 shares in 2008. The repurchases in 2008 were made
under our stock repurchase program at an average price of $10.85. As
of December 31, 2009, 36,007 shares remained authorized for repurchase under our
stock repurchase program. Our Board authorized an additional 100,000
shares in January, bringing the total number of shares authorized for repurchase
under the program to 136,007.
Our cash
balance increased by $1,480,000 during 2009 despite our loss from operations due
largely to the improvement in cash provided by operating activities described
above. We continue to have a high level of liquidity and a strong
financial position as demonstrated by our current ratio, liability to equity
ratio, and high level of working capital. We continue to believe that
our liquid assets are sufficient to fund working capital, R&D, and capital
expenditures for the near term. As the economy continues to improve,
we anticipate that cash flows from operations will generate sufficient cash flow
to meet our long term liquidity needs.
Since
liquidating our investment portfolio during the third quarter of 2008, we have
invested a portion of our excess funds generated from operations in short-term
securities, including money market funds invested in government backed
securities. Our primary goal has been preservation of capital with a
secondary goal of return on invested cash. Because interest rates are
historically low, we have established an investment committee consisting of two
independent directors and our CEO/CFO to evaluate alternative investment options
for excess funds to improve our returns. These investments may
include less than investment grade bonds or other securities that the committee
feels are likely to increase in value and/or provide a higher interest
return. Any such investments made by the Investment Committee are
likely to subject us to a higher risk of loss than our current insured or
government backed investments.
Critical
Accounting Estimates
Our
preparation of financial statements in accordance with accounting principles
generally accepted in the United States of America requires that we utilize key
accounting policies and make certain estimates that could significantly
influence the results of operations and financial position. The most
critical of these accounting policies and estimates include revenue recognition
policies and related warranty reserves, the valuation allowance for inventories,
and uncollectible accounts receivable and intangible asset
valuation.
Revenue Recognition and Warranty
Reserves
We derive revenue from three primary sources: system
sales, parts sales and services. For system and parts sales, we
generally recognize revenue when persuasive evidence of an arrangement exists,
delivery has occurred, the contract price is fixed or determinable, title and
risk of loss have passed to the customer, and collection is reasonably
assured. Our sales are typically not subject to rights of return, and
historically we have not experienced significant sales returns. We
generally record system sales that include installation services as
multiple-element arrangements. In these situations, we recognize
product revenue upon shipment but defer the installation service revenue until
the installation is complete. We defer revenue recognition for the
fair value of any undelivered elements, such as accessories ordered by
customers, until the completion of delivery to the customer. For
certain system sales that involve unique customer acceptance terms or new
specifications or technology with customer acceptance provisions, we do not
recognize revenue until we receive customer acceptance. We record any
deferred revenue from such system sales as an accrued liability.
Our
products generally have a warranty ranging from 90 days to one
year. Upon expiration of the warranty period, the customer may
purchase an extended product warranty typically covering an additional period of
one year. We generally invoice extended warranty billings to the
customer at the beginning of the contract term and recognize the related revenue
ratably over the duration of the contract. Unearned extended warranty
revenue is treated as an accrued liability.
We record
a reserve for warranty expenditures and periodically adjust the amount of the
reserve as required to reflect actual warranty experience. In
determining the warranty reserve, we consider our historical experience and
various additional factors including expected product failure rates, material
usage, and service delivery costs incurred in correcting a product
failure. Should actual product failure rates, material usage, or
service delivery costs differ from our estimates, the estimated warranty
liability could prove to be significantly over or understated. As of
December 31, 2009 and 2008, our warranty liability totaled $246,000 and
$317,000, respectively.
Accounts Receivable
We
maintain an allowance for doubtful accounts representing our estimate of that
portion of accounts receivable which we may be unable to collect from
customers. Customer receivables may prove uncollectible for a variety
of reasons including deterioration of customer financial condition or
dissatisfaction with product performance. We regularly assess
potential doubtful accounts and use the best information available, including
customer correspondence and credit reports. Though our bad debts have
not historically been significant, we could experience increased bad debt
expense should a major customer or market segment experience a financial
downturn or our estimate of uncollectible accounts, which is based on our
historical experience, prove to be inaccurate.
Inventories
Our
inventories consist primarily of electronic equipment and various
components. We operate in a fast-paced industry with frequent
technological advances and new product introductions. Such
occurrences can significantly impair customer demand for our products and the
related inventory we have on hand. We regularly evaluate our
inventory and maintain a reserve for excess or obsolete
inventory. Generally, we record an impairment allowance for products
with no movement in over twelve months that we believe to be either unsalable or
salable only at a reduced selling price. We further use our judgment
in evaluating the recoverability of all inventory based upon known and expected
market conditions as well as future product plans. Should our
competitors introduce a new technology or product that renders our current
products obsolete, our allowance for inventory impairment may be
inadequate.
Our
inventory obsolescence charges totaled $(45,000) and $18,000 in fiscal 2009 and
2008 respectively. The inventory impairment allowance totaled
approximately $594,000 and $654,000 at December 31, 2009 and 2008,
respectively.
Intangible Assets
Our
intangible assets consist primarily of intellectual property, including patents
and patent applications. In accordance with ASC Topic 350
Intangibles—Goodwill and
Other
, we review the recoverability and estimated useful lives of our
intangible assets for impairment whenever events or changes in circumstances
indicate that the carrying amount may not be fully recoverable. As a
result of our reviews, we have not recorded any material impairment charges
during 2009 or 2008.
Inflation
Historically,
neither inflation nor changing prices have had a material impact on our net
revenues or results of operations. However, future inflationary
trends could potentially impact our sales and earnings.
Item
7A. Quantitative and Qualitative Disclosures about Market
Risk
Not
Applicable
Item
8. Financial Statements and Supplementary Data
Management
Responsibility for Financial Reporting.
Management is
responsible for the integrity and objectivity of the data included in this
report. Management believes it has provided financial information
(both audited and unaudited) that is representative of our operations, reliable
on a consistent basis throughout the periods presented and relevant for a
meaningful appraisal of our business. The financial statements have
been prepared in accordance with generally accepted accounting
principles. Where necessary, they reflect estimates based on
management's judgment.
Established
accounting procedures and related systems of internal control provide reasonable
assurance that assets are safeguarded, that the books and records properly
reflect all transactions and that qualified personnel implement policies and
procedures. Management periodically reviews our accounting and
control systems.
Our Audit
Committee, composed of three independent members of the Board of Directors who
are not our employees, meets regularly with representatives of management and
the independent registered public accountants to monitor the functioning of the
accounting and control systems and to review the results of the audit performed
by the independent registered public accountants. The independent
registered public accountants and our employees have full and free access to the
Audit Committee without the presence of management.
The Audit
Committee has full authority and responsibility to oversee the appointment,
termination, funding, evaluation and independence of the independent registered
public accountants engaged by the Company.
The
independent registered public accountants conduct an objective, independent
examination of the financial statements. Their report appears as a
part of this Annual Report on Form 10-K.
Report of
Independent Registered Public Accounting Firm
To the
Board of Directors and Stockholders
O.I.
Corporation
We have
audited the consolidated balance sheets of O. I. Corporation and subsidiary as
of December 31, 2009 and 2008, and the related consolidated statements of
income, stockholders' equity and cash flows for the years then
ended. These financial statements are the responsibility of the
Company's management. Our responsibility is to express an opinion on
these financial statements based on our audits.
We
conducted our audits in accordance with the standards of the Public Company
Accounting Oversight Board (United States). Those standards require
that we plan and perform the audit to obtain reasonable assurance about whether
the financial statements are free of material misstatement. An audit
includes examining, on a test basis, evidence supporting the amounts and
disclosures in the financial statements. An audit also includes
assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement
presentation. We believe that our audits provide a reasonable basis
for our opinion.
In our
opinion, the consolidated financial statements referred to above present fairly,
in all material respects, the financial position of O. I. Corporation and
subsidiary as of December 31, 2009 and 2008, and the results of their operations
and their cash flows for the years then ended, in conformity with U.S. generally
accepted accounting principles.
We were
not engaged to examine management's assessment about the effectiveness of O. I.
Corporation's internal control over financial reporting as of December 31, 2009
included in the accompanying item 9A(T) Controls and Procedures and,
accordingly, we do not express an opinion thereon.
/s/McGLADREY
& PULLEN, LLP
Davenport,
Iowa
March 15,
2010
Consolidated
Balance Sheets
|
|
December 31,
|
|
|
|
2009
|
|
|
2008
|
|
Assets
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Current
assets:
|
|
|
|
|
|
|
Cash
and cash equivalents
|
|
$
|
4,613,741
|
|
|
$
|
3,133,776
|
|
Accounts
receivable-trade, net of allowance for doubtful accounts of $205,765 and
$299,414, respectively
|
|
|
4,371,283
|
|
|
|
6,194,925
|
|
Investment
in sales-type leases-current portion
|
|
|
135,932
|
|
|
|
240,682
|
|
Investments,
at market
|
|
|
-
|
|
|
|
300,000
|
|
Inventories,
net
|
|
|
5,656,546
|
|
|
|
5,754,440
|
|
Current
deferred income tax assets
|
|
|
650,934
|
|
|
|
824,883
|
|
Other
current assets
|
|
|
1,041,253
|
|
|
|
488,464
|
|
Total
current assets
|
|
|
16,469,689
|
|
|
|
16,937,170
|
|
|
|
|
|
|
|
|
|
|
Property,
plant and equipment, net
|
|
|
2,786,526
|
|
|
|
3,158,526
|
|
Investment
in sales-type leases, net of current
|
|
|
236,342
|
|
|
|
357,770
|
|
Long-term
deferred income tax assets
|
|
|
565,613
|
|
|
|
657,075
|
|
Intangible
assets, net
|
|
|
506,730
|
|
|
|
462,178
|
|
Other
assets
|
|
|
22,210
|
|
|
|
31,622
|
|
Total
assets
|
|
$
|
20,587,110
|
|
|
$
|
21,604,341
|
|
|
|
|
|
|
|
|
|
|
Liabilities
and Stockholders’ Equity
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Current
liabilities:
|
|
|
|
|
|
|
|
|
Accounts
payable, trade
|
|
$
|
1,076,745
|
|
|
$
|
1,516,184
|
|
Accrued
compensation and other related expenses
|
|
|
761,052
|
|
|
|
1,281,151
|
|
Accrued
liabilities
|
|
|
1,030,561
|
|
|
|
845,713
|
|
Total
current liabilities
|
|
|
2,868,358
|
|
|
|
3,643,048
|
|
|
|
|
|
|
|
|
|
|
Uncertain
Tax Positions-Long Term
|
|
|
26,829
|
|
|
|
26,829
|
|
|
|
|
|
|
|
|
|
|
Commitments
and contingencies
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders’
equity:
|
|
|
|
|
|
|
|
|
Preferred
stock, $0.10 par value, 3,000,000 shares authorized, no shares issued and
outstanding
|
|
|
-
|
|
|
|
-
|
|
Common
stock, $0.10 par value, 10,000,000 shares authorized, 4,103,377 shares
issued
|
|
|
410,338
|
|
|
|
410,338
|
|
Additional
paid-in capital
|
|
|
5,514,690
|
|
|
|
5,401,593
|
|
Treasury
stock, 1,740,262 and 1,754,147 shares, respectively, at
cost
|
|
|
(13,133,747
|
)
|
|
|
(13,194,868
|
)
|
Retained
earnings
|
|
|
24,900,642
|
|
|
|
25,317,401
|
|
|
|
|
17,691,923
|
|
|
|
17,934,464
|
|
Total
liabilities and stockholders’ equity
|
|
$
|
20,587,110
|
|
|
$
|
21,604,341
|
|
The
accompanying notes are an integral part of these consolidated financial
statements.
Consolidated
Statements of Income
|
|
Years Ended December 31
|
|
|
|
2009
|
|
|
2008
|
|
|
|
|
|
|
|
|
Net
revenues:
|
|
|
|
|
|
|
Products
|
|
$
|
16,688,854
|
|
|
$
|
25,405,165
|
|
Services
|
|
|
3,223,069
|
|
|
|
3,563,935
|
|
Total
net revenues
|
|
|
19,911,923
|
|
|
|
28,969,100
|
|
|
|
|
|
|
|
|
|
|
Cost
of revenues:
|
|
|
|
|
|
|
|
|
Products
|
|
|
8,808,744
|
|
|
|
13,025,895
|
|
Services
|
|
|
1,331,221
|
|
|
|
1,676,092
|
|
Total
cost of revenues
|
|
|
10,139,965
|
|
|
|
14,701,987
|
|
Gross
profit
|
|
|
9,771,958
|
|
|
|
14,267,113
|
|
|
|
|
|
|
|
|
|
|
Selling,
general and administrative expenses
|
|
|
6,891,606
|
|
|
|
8,956,131
|
|
Research
and development expenses
|
|
|
2,985,437
|
|
|
|
3,850,872
|
|
Operating
(loss)/income
|
|
|
(105,085
|
)
|
|
|
1,460,110
|
|
Other
income:
|
|
|
|
|
|
|
|
|
Interest
income, net
|
|
|
32,639
|
|
|
|
107,932
|
|
Other
income/(loss)
|
|
|
16,338
|
|
|
|
(572,144
|
)
|
(Loss)/income
before income taxes
|
|
|
(56,108
|
)
|
|
|
995,898
|
|
Benefit
for income taxes
|
|
|
110,662
|
|
|
|
24,049
|
|
|
|
|
|
|
|
|
|
|
Net
income
|
|
$
|
54,554
|
|
|
$
|
1,019,947
|
|
|
|
|
|
|
|
|
|
|
Basic
earnings per share
|
|
$
|
0.02
|
|
|
$
|
0.40
|
|
Diluted
earnings per share
|
|
$
|
0.02
|
|
|
$
|
0.40
|
|
|
|
|
|
|
|
|
|
|
Weighted
average number of shares outstanding:
|
|
|
|
|
|
|
|
|
Basic
shares
|
|
|
2,356,142
|
|
|
|
2,539,358
|
|
Diluted
shares
|
|
|
2,367,794
|
|
|
|
2,573,814
|
|
The
accompanying notes are an integral part of these consolidated financial
statements.
Consolidated
Statements of Cash Flows
|
|
Years Ended December 31
|
|
|
|
2009
|
|
|
2008
|
|
Cash
flows from operating activities:
|
|
|
|
|
|
|
Net
income
|
|
$
|
54,554
|
|
|
$
|
1,019,947
|
|
Adjustments
to reconcile net income to net cash
|
|
|
|
|
|
|
|
|
provided
by operating activities:
|
|
|
|
|
|
|
|
|
Depreciation
and amortization
|
|
|
526,044
|
|
|
|
612,219
|
|
Stock
based compensation
|
|
|
105,740
|
|
|
|
157,316
|
|
Provision
for obsolete inventory
|
|
|
44,572
|
|
|
|
(18,094
|
)
|
Deferred
income tax expense/(benefit)
|
|
|
265,411
|
|
|
|
(32,712
|
)
|
Gain
on disposition of property
|
|
|
(2,440
|
)
|
|
|
(11,998
|
)
|
Loss
on sale of securities including amortization of discounts
|
|
|
-
|
|
|
|
692,144
|
|
Changes
in assets and liabilities:
|
|
|
|
|
|
|
|
|
Accounts
receivable
|
|
|
1,823,642
|
|
|
|
736,469
|
|
Inventories
|
|
|
53,322
|
|
|
|
(379,566
|
)
|
Other
current assets and investments in sales-type leases
|
|
|
(330,667
|
)
|
|
|
(230,676
|
)
|
Accounts
payable
|
|
|
(439,439
|
)
|
|
|
(355,661
|
)
|
Accrued
liabilities
|
|
|
(335,251
|
)
|
|
|
(858,515
|
)
|
Net
cash provided by operating activities
|
|
|
1,765,488
|
|
|
|
1,330,873
|
|
|
|
|
|
|
|
|
|
|
Cash
flows from investing activities:
|
|
|
|
|
|
|
|
|
Purchase
of property, plant, and equipment
|
|
|
(160,333
|
)
|
|
|
(348,293
|
)
|
Proceeds
from sale of property, plant, and equipment
|
|
|
28,500
|
|
|
|
53,722
|
|
Purchase
of investments
|
|
|
-
|
|
|
|
(3,181,301
|
)
|
Maturity/proceeds
from sales of investments
|
|
|
300,000
|
|
|
|
5,506,886
|
|
Change
in other assets
|
|
|
(64,323
|
)
|
|
|
(72,155
|
)
|
Net
cash provided by investing activities
|
|
|
103,844
|
|
|
|
1,958,859
|
|
|
|
|
|
|
|
|
|
|
Cash
flows from financing activities:
|
|
|
|
|
|
|
|
|
Purchase
of treasury stock
|
|
|
(7,080
|
)
|
|
|
(3,086,671
|
)
|
Proceeds
from issuance of treasury stock
|
|
|
89,026
|
|
|
|
80,503
|
|
Payment
of cash dividends on common stock
|
|
|
(471,313
|
)
|
|
|
(505,641
|
)
|
Net
cash used in financing activities
|
|
|
(389,367
|
)
|
|
|
(3,511,809
|
)
|
|
|
|
|
|
|
|
|
|
Net increase
(decrease) in cash and cash equivalents
|
|
|
1,479,965
|
|
|
|
(222,077
|
)
|
Beginning
of year
|
|
|
3,133,776
|
|
|
|
3,355,853
|
|
End
of year
|
|
$
|
4,613,741
|
|
|
$
|
3,133,776
|
|
|
|
|
|
|
|
|
|
|
Supplemental
disclosures of cash flow information:
|
|
|
|
|
|
|
|
|
Cash
paid during year for:
|
|
|
|
|
|
|
|
|
Income
taxes, net of refunds
|
|
$
|
(167,915
|
)
|
|
$
|
332,147
|
|
The
accompanying notes are an integral part of these consolidated financial
statements.
Consolidated
Statements of Stockholders' Equity
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated
|
|
|
|
|
|
|
|
|
|
Additional
|
|
|
|
|
|
|
|
|
Other
|
|
|
Total
|
|
|
|
Common
Stock
|
|
|
Paid-In
|
|
|
Treasury
|
|
|
Retained
|
|
|
Comprehensive
|
|
|
Stockholders’
|
|
|
|
Shares
|
|
|
Amount
|
|
|
Capital
|
|
|
Stock
|
|
|
Earnings
|
|
|
Income
(Loss)
|
|
|
Equity
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance,
December 31, 2007
|
|
$
|
4,103,377
|
|
|
$
|
410,338
|
|
|
$
|
5,288,385
|
|
|
$
|
(10,232,808
|
)
|
|
$
|
24,803,095
|
|
|
$
|
(147,008
|
)
|
|
$
|
20,122,002
|
|
Purchase
of 284,569 shares of treasury stock
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(3,086,671
|
)
|
|
|
-
|
|
|
|
-
|
|
|
|
(3,086,671
|
)
|
Issuance
of 11,300 shares from treasury for exercise of stock
options
|
|
|
-
|
|
|
|
-
|
|
|
|
(751
|
)
|
|
|
53,110
|
|
|
|
-
|
|
|
|
-
|
|
|
|
52,359
|
|
Issuance
of 2,447 shares from treasury to Employee Stock Purchase
Plan
|
|
|
-
|
|
|
|
-
|
|
|
|
16,643
|
|
|
|
11,501
|
|
|
|
-
|
|
|
|
-
|
|
|
|
28,144
|
|
Vesting
of 12,000 shares granted to new board of directors in 2006
|
|
|
-
|
|
|
|
-
|
|
|
|
(60,000
|
)
|
|
|
60,000
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
Stock-based
compensation expense
|
|
|
-
|
|
|
|
-
|
|
|
|
157,316
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
157,316
|
|
Dividends
paid
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(505,641
|
)
|
|
|
-
|
|
|
|
(505,641
|
)
|
Comprehensive
income:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Unrealized
gain on investments, net of deferred tax expense of
$50,947
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
147,008
|
|
|
|
147,008
|
|
Net
income
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
1,019,947
|
|
|
|
-
|
|
|
|
1,019,947
|
|
Total
comprehensive income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,166,955
|
|
Balance,
December 31, 2008
|
|
|
4,103,377
|
|
|
|
410,338
|
|
|
|
5,401,593
|
|
|
|
(13,194,868
|
)
|
|
|
25,317,401
|
|
|
|
-
|
|
|
|
17,934,464
|
|
Purchase
of 1,000 shares of treasury stock
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(7,080
|
)
|
|
|
-
|
|
|
|
-
|
|
|
|
(7,080
|
)
|
Issuance
of 7,350 shares from treasury for exercise of stock
options
|
|
|
-
|
|
|
|
-
|
|
|
|
(1,676
|
)
|
|
|
33,823
|
|
|
|
-
|
|
|
|
-
|
|
|
|
32,147
|
|
Issuance
of 7,535 shares from treasury to Employee Stock Purchase
Plan
|
|
|
-
|
|
|
|
-
|
|
|
|
22,501
|
|
|
|
34,378
|
|
|
|
-
|
|
|
|
-
|
|
|
|
56,879
|
|
Stock-based
compensation expense
|
|
|
-
|
|
|
|
-
|
|
|
|
105,740
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
105,740
|
|
Dividends
paid
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(471,313
|
)
|
|
|
-
|
|
|
|
(471,313
|
)
|
Tax
benefits related to non-qualifying stock options
|
|
|
-
|
|
|
|
-
|
|
|
|
(13,468
|
)
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(13,468
|
)
|
Net
income and comprehensive income
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
54,554
|
|
|
|
-
|
|
|
|
54,554
|
|
Balance,
December 31, 2009
|
|
|
4,103,377
|
|
|
$
|
410,338
|
|
|
$
|
5,514,690
|
|
|
$
|
(13,133,747
|
)
|
|
$
|
24,900,642
|
|
|
$
|
-
|
|
|
$
|
17,691,923
|
|
The
accompanying notes are an integral part of these consolidated financial
statements.
O.I.
CORPORATION
Notes
to Consolidated Financial Statements
Note
1. Organization and Summary of Significant Accounting
Policies
O.I.
Corporation, an Oklahoma corporation, was organized in 1963. O.I.
Corporation designs, manufactures, markets and services analytical, monitoring
and sample preparation products, components and systems used to detect, measure
and analyze chemical compounds in air and water.
Summary
of Significant Accounting Policies
Principles of
Consolidation
The consolidated financial statements have been
prepared in accordance with accounting principles generally accepted in the
United States of America and include the accounts of O.I. Corporation and its
wholly owned subsidiary (collectively, the “Company” or “OI”). All
significant intercompany transactions and balances have been eliminated in the
consolidated financial statements.
Revenue
Recognition and Warranty Reserve
The Company derives revenues from three
primary sources—system sales, parts sales and services. For system
sales and parts sales, revenue is generally recognized when persuasive evidence
of an arrangement exists, delivery has occurred, the contract price is fixed or
determinable, title and risk of loss has passed to the customer and collection
is reasonably assured. The Company’s sales are typically not subject
to rights of return and, historically, sales returns have not been
significant. System sales that do not involve unique customer
acceptance terms or new specifications or technology with customer acceptance
provisions and that involve installation services are accounted for as
multiple-element arrangements, where the fair value of the installation service
is deferred when the product is delivered and recognized when the installation
is complete. In all cases, the fair value of undelivered elements,
such as accessories ordered by customers, is deferred until the related items
are delivered to the customer. For certain other system sales that do
involve unique customer acceptance terms or new specifications or technology
with customer acceptance provisions, all revenue is generally deferred until
customer acceptance. Deferred revenue from such system sales is
presented as unearned revenues in accrued liabilities in the accompanying
consolidated balance sheets.
Our
products generally carry a warranty ranging from 90 days to one
year. Once the warranty period has expired, the customer may purchase
an extended product warranty typically covering an additional period of one
year. Extended warranty billings are generally invoiced to the
customer at the beginning of the contract term. Revenue from extended
warranties is deferred and recognized ratably over the duration of the
contract. Unearned extended warranty revenue is included in unearned
revenues in accrued liabilities in the accompanying consolidated balance
sheets.
Taxes
collected from customers and remitted to government agencies for specific
revenue producing transactions are recorded net with no effect on the income
statement.
Shipping and
Handling Costs
Shipping and handling costs are included in products cost
of revenues.
Cash and Cash
Equivalents
The Company considers all highly liquid cash investment
instruments with an original maturity of three months or less to be cash
equivalents. Included in cash and cash equivalents at December 31,
2009 and 2008 are cash investments in money market funds of $3,173,000 and
$2,874,000 all of which were invested in government
securities. Additionally, the Company had at December 31, 2009 and
2008, $1,737,000 and $27,000, respectively, of cash balances in excess of the
Federal Deposit Insurance Corporation (FDIC) limits.
Accounts
Receivable
The Company maintains allowances for doubtful accounts for
estimated losses resulting from the failure of its customers to make required
payments and for estimated sales returns. Customers may not make
payments due to a variety of reasons including deterioration of their financial
condition or dissatisfaction with the Company’s products. Management
makes regular assessments of doubtful accounts and uses the best information
available including correspondence with customers and credit
reports. The Company periodically accrues for bad debt and management
regularly compares uncollectible accounts with period end accounts receivable
balances to determine its adequacy. For the years ended December 31,
2009 and 2008 we recognized approximately $24,000 and $78,000 of bad debt
expense, respectively.
Investments
The Company accounts for its investments using ASC Topic 320
Investments-Debt and Equity
Securities
. This guidance requires that certain debt and
equity securities be adjusted to market value at the end of each accounting
period. The Company had no investments as of December 31,
2009. The Company’s investments as of December 31, 2008 consisted of
highly liquid, government backed or government insured
instruments. These investments were classified as available-for-sale
and are stated at fair value at December 31, 2008. Realized gains and
losses on sales of investments are determined on a specific identification basis
and included in the consolidated statements of income. Declines in
the fair value of individual available-for-sale securities below their carrying
value that are deemed other than temporary, result in write-downs of the
individual securities to their fair value with the resulting loss charged to
current period income. We had no such declines in 2009, but during
2008, we liquidated our investment holdings of preferred stock and corporate
bonds and recognized a loss of $713,000.
Investment in
Sales-Type Leases
The Company’s leasing operations consist of leasing
analytical instruments. All of the Company’s leases are classified as
sales-type leases. These leases typically expire over a four-year
period. The Company recognizes as revenues the principal portion of
sales-type leases upon initiation of the lease. Interest is deferred
and recognized as revenues over the initial term of the
lease. Security deposits are deferred until the lease expires and are
either recognized as revenues or returned to the customer, as
appropriate.
Inventories
Inventories consist of electronic equipment and various components and are
stated at the lower of cost or market. Cost is determined on a
standard cost basis, which approximates the first-in first-out
basis. The Company maintains a reserve for inventory obsolescence and
regularly evaluates its inventory. Items with no movement in twelve
months or more are generally reserved or written off. The Company
also provides for impairment of items that have realizable value below
cost.
Property, Plant,
and Equipment
Property, plant, and
equipment is recorded at cost and depreciated over the estimated useful lives of
3 to 40 years using the straight-line method. Improvements of leased
properties are amortized over the shorter of the life of the applicable lease
term or the estimated useful life. Repairs and maintenance are
expensed as incurred.
Intangible
Assets
Intangible assets
primarily consist of patent applications and issued patents. Patent applications
are capitalized upon issuance of a final patent or expensed upon abandonment or
withdrawal. Upon issuance, patents are amortized on a straight-line
basis over their estimated useful lives of seventeen years. U.S. GAAP
requires that long-lived assets, including intangible assets, be reviewed for
impairment whenever changes in circumstances indicate that the carrying value
may not be recoverable. The carrying value is considered impaired
when the anticipated separately identifiable undiscounted cash flows from such
an asset are less than the carrying value of the asset. In that
event, a loss is recognized based on the amount by which the carrying value
exceeds the fair value of the long-lived asset.
Product
Warranties
Products are sold with
warranties ranging from 90 days to one year, and extended warranties may be
purchased for some products. The Company establishes a reserve for
warranty expenditures and periodically adjusts the amount of the reserve as
required based on actual warranty experience. The Company makes
estimates of these costs based on historical experience and on various other
assumptions including historical and expected product failure rates, material
usage, and service delivery costs incurred in correcting a product
failure. Should actual product failure rates, material usage, or
service delivery costs differ from estimates, revisions to the estimated
warranty liability would be required.
Research and
Development Costs
Research and development costs are expensed as
incurred.
Advertising
Costs
All
advertising costs are expensed as incurred and are included in selling and
administrative expenses in the consolidated statements of
income. Advertising expenses for 2009 and 2008 were $141,968 and
$180,679, respectively.
Income
Taxes
The Company provides for deferred taxes in accordance with ASC
Topic 740
Income Taxes
,
which requires the Company to use the asset and liability approach to account
for income taxes. This approach requires the recognition of deferred
income tax liabilities and assets for the expected future tax consequences of
temporary differences between the carrying amounts and the tax bases of assets
and liabilities. The provision for income taxes is based on income
before income taxes as reported in the accompanying consolidated statements of
income. The Company recognizes tax benefits for uncertain tax
positions when they satisfy a greater than 50% probability threshold and
provides for the estimated impact of interest and penalties for the uncertain
tax benefits.
Financial
Instruments
ASC
Topic 825
Financial
Instruments
defines the fair value of financial instruments as the amount
at which the instrument could be exchanged in a current transaction between
willing parties. Due to their near-term maturities, the carrying amounts of cash
and cash equivalents, accounts receivable and accounts payable are considered
equivalent to fair value. The Company does not have any off-balance sheet
financial instruments.
Concentrations of
Credit Risk
Financial instruments, which potentially subject the Company
to concentrations of credit risk, consist principally of trade
receivables. The Company sells its products primarily to large
corporations, environmental testing laboratories and governmental
agencies. The majority of its customers are located in the U.S. and
all sales are denominated in U.S. dollars. The Company performs
ongoing credit evaluations of its customers to minimize credit
risk. However, agencies of the U.S. Government constitute a
significant percentage of the Company’s revenues (See Note 14). Any
federal budget cuts or changes in regulations affecting the U.S. chemical
warfare programs or the U.S. Environmental Protection Agency may have a negative
impact on the Company's future revenues.
Earnings Per
Share
The Company reports both basic earnings per share, which is based
on the weighted average number of common shares outstanding, and diluted
earnings per share, which is based on the weighted average number of common
shares outstanding and all dilutive potential common shares
outstanding. Stock options are the only dilutive potential shares the
Company has outstanding. At December 31, 2009 and 2008 options to
acquire 100,000 and 88,000 shares at the weighted average exercise prices of
$12.06 and $12.88, respectively, were not included in the computations of
dilutive earnings per share as their effect would be
anti-dilutive. The following table sets forth the computation of
basic and diluted earnings per share:
|
|
Year Ended December 31,
|
|
|
|
2009
|
|
|
2008
|
|
Numerator,
earnings attributable to common stockholders
|
|
$
|
54,554
|
|
|
$
|
1,019,947
|
|
Denominator:
|
|
|
|
|
|
|
|
|
Basic-weighted
average common shares outstanding
|
|
|
2,356,142
|
|
|
|
2,539,358
|
|
Dilutive
effect of employee stock options
|
|
|
11,652
|
|
|
|
34,456
|
|
Diluted
outstanding shares
|
|
$
|
2,367,794
|
|
|
$
|
2,573,814
|
|
|
|
|
|
|
|
|
|
|
Basic
earnings per common share
|
|
$
|
0.02
|
|
|
$
|
0.40
|
|
Diluted
earnings per common share
|
|
$
|
0.02
|
|
|
$
|
0.40
|
|
Stock-Based
Compensation
On January 1, 2006, we adopted the provisions of ASC Topic
718
Compensation-Stock
Compensation
which requires us to recognize expense related to the fair
value of our stock-based compensation awards, including employee stock
options.
Use of
Estimates
The preparation of the consolidated financial statements in
accordance with accounting principles generally accepted in the United States of
America requires the use of management’s estimates. These estimates
are subjective in nature and involve judgments that affect the reported amounts
of assets and liabilities, the disclosure of contingent assets and liabilities
at year-end and the reported amounts of revenues and expenses during the
year. Actual results could differ from those estimates.
We record
a reserve for warranty expenditures and periodically adjust the amount of the
reserve as required to reflect actual warranty experience. In
determining the warranty reserve, we consider our historical experience and
various additional factors including expected product failure rates, material
usage and service delivery costs incurred in correcting a product
failure.
We
maintain an allowance for doubtful accounts representing our estimate of that
portion of accounts receivable which we may be unable to collect from
customers. Customer receivables may prove uncollectible for a variety
of reasons including deterioration of customer financial condition, damage
during shipment, or dissatisfaction with product performance. We
regularly assess potential doubtful accounts and use the best information
available, including customer correspondence and credit reports.
We
regularly evaluate our inventory and maintain a reserve for excess or obsolete
inventory. Generally, we record an impairment allowance for products
with no movement in over twelve months that we believe to be either unsalable,
or salable only at a reduced selling price. We further use our
judgment in evaluating the recoverability of all inventory based upon known and
expected market conditions as well as future product plans.
Recent
Pronouncements
In June
2009 the Financial Accounting Standards Board (“FASB”) issued Statement of
Financial Accounting Standards No. 168 “The FASB Accounting Standards
Codification and the Hierarchy of Generally Accepted Accounting Principles—a
replacement of FASB Standard No. 162” (“SFAS 168”). SFAS 168 replaces the
Generally Accepted Accounting Principles (“GAAP”) with two levels of GAAP:
authoritative and non-authoritative. On July 1, 2009, the FASB Accounting
Standards Codification (“ASC”) became the single source of authoritative
nongovernmental GAAP, except for rules and interpretive releases of the
Securities and Exchange Commission. All other non-grandfathered accounting
literature became non-authoritative. The adoption of SFAS 168 did not have a
material impact on our consolidated financial statements. As a result of the
adoption of SFAS 168, all references to GAAP now refer to the codified ASC
topic.
In
September 2006, ASC Topic 820 was issued which defines fair value, establishes a
framework for measuring fair value in generally accepted accounting principles,
and expands disclosures about fair value measurements. ASC Topic 820 does not
require any new fair value measurements, but provides guidance on how to measure
fair value by providing a fair value hierarchy used to classify the source of
the information. We adopted the provisions of ASC Topic 820 on January 1, 2009.
The adoption of ASC Topic 820 did not have a significant impact on our
consolidated financial statements.
In April
2009, ASC Topic 855 was issued which establishes general standards of accounting
for and disclosure of events that occur after the balance sheet date but before
financial statements are issued or available to be issued. We adopted ASC Topic
855 for the quarter ending June 30, 2009. The adoption did not have a
material impact on our consolidated financial statements
Note
2. Net Investment in Sales-Type Leases
The
following lists the components of the net investment in sales-type leases as of
December 31:
|
|
2009
|
|
|
2008
|
|
|
|
|
|
|
|
|
Total
minimum lease payments to be received
|
|
$
|
372,274
|
|
|
$
|
598,452
|
|
Less: Unearned
income
|
|
|
(34,547
|
)
|
|
|
(59,904
|
)
|
Net
investment in sales-type leases
|
|
$
|
337,727
|
|
|
$
|
538,548
|
|
At
December 31, 2009, minimum lease payments for each of the five succeeding fiscal
years are as follows: $135,932 in 2010, $106,109 in 2011, $89,743 in
2012, $40,490 in 2013, and $0 in 2014.
Note
3. Inventories
Inventories,
which include material, labor and manufacturing overhead, on December 31, 2009
and 2008, consisted of the following:
|
|
2009
|
|
|
2008
|
|
|
|
|
|
|
|
|
Raw
materials
|
|
$
|
4,762,602
|
|
|
$
|
4,838,613
|
|
Work-in-process
|
|
|
415,000
|
|
|
|
485,734
|
|
Finished
goods
|
|
|
1,072,774
|
|
|
|
1,083,841
|
|
Reserves
|
|
|
(593,830
|
)
|
|
|
(653,748
|
)
|
|
|
$
|
5,656,546
|
|
|
$
|
5,754,440
|
|
A
provision for obsolete inventory was determined in 2009 and 2008 by taking the
total of the inventory related to discontinued products, and consistent with the
Company’s policy relating to obsolete inventory, the total of other inventory
with no movement in twelve months including excess which the Company determined
is no longer saleable based on available market information. The
provision for obsolete inventory totaled approximately $(45,000)
in 2009 and approximately
$18,000 in 2008. These provisions are included in cost of revenues in
the consolidated statements of income.
Note
4. Property, Plant and Equipment
Property,
plant and equipment at cost on December 31, 2009 and 2008, consisted of the
following:
|
|
Estimated
|
|
|
|
|
|
|
|
|
Useful
|
|
|
|
|
|
|
|
|
Lives
|
|
2009
|
|
|
2008
|
|
|
|
|
|
|
|
|
|
|
Land
|
|
|
|
$
|
38,922
|
|
|
$
|
38,922
|
|
Buildings
|
|
33
to 40 Years
|
|
|
3,844,683
|
|
|
|
3,843,083
|
|
Leasehold
improvements
|
|
1
to 5 Years
|
|
|
149,343
|
|
|
|
149,343
|
|
Furniture
and equipment
|
|
3
to 10 Years
|
|
|
4,443,540
|
|
|
|
4,905,192
|
|
|
|
|
|
|
8,476,488
|
|
|
|
8,936,540
|
|
Less
accumulated depreciation
|
|
|
|
|
5,689,962
|
|
|
|
5,778,014
|
|
|
|
|
|
$
|
2,786,526
|
|
|
$
|
3,158,526
|
|
Depreciation
expense totaled $506,273 and $593,601 for the years ended December 31, 2009 and
2008, respectively.
Note
5. Investments
Investments
considered available-for-sale at December 31, 2008, consisted of certificates of
deposit which were all due within one year and whose fair value approximated
cost.
For the
years ended December 31, 2009 and 2008, proceeds from sales of securities
available for sale amounted to $300,000 and $5,506,886,
respectively. Gross realized gains amounted to $0 and $24,026 in 2009
and 2008, respectively. Gross recognized losses amounted to $0 and
$737,275 in 2009 and 2008, respectively. For the years ended December
31, 2009 and 2008, dividend income amounted to $1,522 and $104,086,
respectively.
Note
6. Intangible Assets
Intangible
assets on December 31, 2009 and 2008 consisted of the following:
|
|
2009
|
|
|
2008
|
|
|
|
Gross
|
|
|
|
|
|
Gross
|
|
|
|
|
|
|
Carrying
|
|
|
Accumulated
|
|
|
Carrying
|
|
|
Accumulated
|
|
|
|
Amount
|
|
|
Amortization
|
|
|
Amount
|
|
|
Amortization
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Patents
Issued
|
|
$
|
289,526
|
|
|
$
|
(145,014
|
)
|
|
$
|
293,477
|
|
|
$
|
(191,127
|
)
|
Patent
Applications Pending
|
|
|
288,100
|
|
|
|
-
|
|
|
|
279,534
|
|
|
|
-
|
|
Rights
to licenses
|
|
|
105,000
|
|
|
|
(30,882
|
)
|
|
|
105,000
|
|
|
|
(24,706
|
)
|
|
|
$
|
682,626
|
|
|
$
|
(175,896
|
)
|
|
$
|
678,011
|
|
|
$
|
(215,833
|
)
|
Our
intangible assets consist primarily of intellectual property, including patents
and patent applications. When a new patent is granted, we begin
amortizing the cost over the life of the patent. Amortization expense
charged to operations amounted to $19,771 and $18,618, for the years ended
December 31, 2009 and 2008, respectively.
Estimated
future amortization expense on rights to licenses and existing patents issued
for fiscal years ending December 31, are as follows:
2010
|
|
$
|
19,235
|
|
2011
|
|
|
18,128
|
|
2012
|
|
|
17,752
|
|
2013
|
|
|
17,475
|
|
2014
|
|
|
14,153
|
|
Each
year, the Company performs an annual evaluation of the future prospects of
certain products and their related inventory and intangible
assets. The Company evaluated its remaining intangible assets in 2009
and in 2008 and determined that no impairment charge was necessary.
Note
7. Accrued Liabilities
Accrued
liabilities on December 31, 2009 and 2008 consisted of the
following:
|
|
2009
|
|
|
2008
|
|
|
|
|
|
|
|
|
Unearned
revenues
|
|
$
|
23,421
|
|
|
$
|
28,021
|
|
Unearned
revenues - service contracts
|
|
|
294,924
|
|
|
|
224,823
|
|
Unearned
revenues/deposits - sales-type leases
|
|
|
53,022
|
|
|
|
126,233
|
|
Accrued
warranties
|
|
|
245,894
|
|
|
|
316,728
|
|
Other
liabilities and accrued expenses
|
|
|
413,300
|
|
|
|
149,908
|
|
|
|
$
|
1,030,561
|
|
|
$
|
845,713
|
|
Note
8. Product Warranty Liabilities
The
changes in the Company’s product warranty liability for the years ended December
31, 2009 and 2008 are as follows:
|
|
2009
|
|
|
2008
|
|
|
|
|
|
|
|
|
Liabilities,
beginning of year
|
|
$
|
316,728
|
|
|
$
|
495,728
|
|
Expense
for new warranties issued
|
|
|
115,309
|
|
|
|
159,702
|
|
Warranty
claims
|
|
|
(186,143
|
)
|
|
|
(338,702
|
)
|
Liabilities,
end of year
|
|
$
|
245,894
|
|
|
$
|
316,728
|
|
Note
9. Stock Option and Stock Purchase Plan
Incentive
Compensation Plans
We have
two stock option plans, one of which has expired and one with shares available
for grant at December 31, 2009. Our 2003 Incentive Compensation Plan
is in effect until December 31, 2012 and has 190,700 shares available for grant
as of December 31, 2009 with a minimum exercise price as a percentage of fair
market value at date of grant of 100%.
Option
grants under both plans have a contractual life of ten years. Grants
to non-employee directors made prior to November 2007 have a contractual life of
three years; grants made during and after November 2007 have a contractual life
of ten years. Option grants vest equally on each anniversary of the
grant date, commencing with the first anniversary, except grants to non-employee
directors. Grants made to non-employee directors prior to November
2007 vest in full six months after the grant date; grants made during and after
November 2007 vest in full on the first anniversary of the grant
date. We recognize compensation cost for these awards on a
straight-line basis over the service period based on the grant date fair
value.
Our
pre-tax compensation cost for stock-based compensation was, $106,000 and
$157,000 for the years ended December 31, 2009 and 2008,
respectively. No incentive stock options were granted during the
years ended December 31, 2009 and 2008.
The
following is a summary of the changes in outstanding options for the twelve
months ended December 31, 2008 and 2009:
|
|
|
|
|
|
|
|
Weighted
Average
|
|
|
|
Shares
|
|
|
Price Per Share
|
|
|
Price Per Share
|
|
|
|
|
|
|
|
|
|
|
|
Options
outstanding, December 31, 2007
|
|
|
186,550
|
|
|
|
2.50
- 13.70
|
|
|
|
9.31
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Options
granted
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
Options
exercised
|
|
|
(11,300
|
)
|
|
|
3.13
- 8.36
|
|
|
|
4.63
|
|
Options
forfeited or cancelled
|
|
|
(15,700
|
)
|
|
|
3.50
- 12.35
|
|
|
|
9.22
|
|
Options
outstanding, December 31, 2008
|
|
|
159,550
|
|
|
|
2.50
- 13.70
|
|
|
|
9.82
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Options
granted
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
Options
exercised
|
|
|
(7,350
|
)
|
|
|
3.88
- 5.63
|
|
|
|
4.37
|
|
Options
forfeited or cancelled
|
|
|
(15,400
|
)
|
|
|
4.03
- 13.70
|
|
|
|
9.20
|
|
Options
outstanding, December 31, 2009
|
|
|
136,800
|
|
|
|
3.13
- 13.70
|
|
|
|
10.18
|
|
There
were 106,800 and 108,000 share options exercisable at December 31, 2009 and
2008, respectively.
The
following table summarizes significant ranges of outstanding and exercisable
options at December 31, 2009:
|
|
Options Outstanding
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted
|
|
|
|
|
|
Options Exercisable
|
|
|
|
|
|
|
Average
|
|
|
Weighted
|
|
|
|
|
|
Weighted
|
|
|
|
|
|
|
Remaining
|
|
|
Average
|
|
|
|
|
|
Average
|
|
Ranges of
|
|
|
|
|
Life in
|
|
|
Exercise
|
|
|
|
|
|
Exercise
|
|
Exercise Prices
|
|
Shares
|
|
|
Years
|
|
|
Price
|
|
|
Shares
|
|
|
Price
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$3.13
- $6.52
|
|
|
36,800
|
|
|
|
2.4
|
|
|
$
|
5.08
|
|
|
|
36,800
|
|
|
$
|
5.08
|
|
$8.36
- $12.35
|
|
|
51,000
|
|
|
|
4.5
|
|
|
$
|
10.49
|
|
|
|
41,000
|
|
|
$
|
10.27
|
|
$13.70
- $13.70
|
|
|
49,000
|
|
|
|
7.5
|
|
|
$
|
13.70
|
|
|
|
29,000
|
|
|
$
|
13.70
|
|
As of December 31, 2009
|
|
Shares
|
|
|
Intrinsic
Value
|
|
|
|
|
|
|
|
|
Total
outstanding in-the-money options
|
|
|
36,800
|
|
|
|
117,606
|
|
Total
vested in-the-money options
|
|
|
36,800
|
|
|
|
117,606
|
|
Total
options exercised in 2009
|
|
|
7,350
|
|
|
|
27,960
|
|
The total
intrinsic value of share options exercised for the twelve months ended December
31, 2009 and 2008 was $27,960 and $69,561, respectively. No options
were granted in 2009 or 2008.
During
the twelve months ended December 31, 2009 and 2008, proceeds received by the
Company from the exercise of options were $32,000 and $52,000,
respectively. At December 31, 2009, total unrecognized stock-based
compensation expense related to unvested stock options was approximately
$143,000, which is expected to be recognized over a weighted average period of
approximately 1.3 years.
Note
10. Stockholders’ Equity
The
Company’s Articles of Incorporation authorize the issuance of up to 3,000,000
shares of preferred stock with $0.10 par value per share. The voting
rights, dividend rate, redemption price, rights of conversion, rights upon
liquidation and other preferences are subject to determination by the Board of
Directors. As of December 31, 2009, no preferred stock had been
issued and none is outstanding.
The
Company’s Board of Directors has authorized the Company to repurchase shares of
its common stock through open market purchases or privately negotiated
transactions. The Company repurchased 1,000 and 284,569 shares in
2009 and 2008, respectively. The Company accounts for repurchased
shares using the cost method. As of December 31, 2009 the Company is
authorized to repurchase up to 36,007 additional shares of its common
stock.
Note
11. Income Taxes
The
Company’s operations are only taxed under domestic jurisdictions.
The
benefit for income taxes is summarized as follows:
|
|
Year Ended December 31,
|
|
|
|
2009
|
|
|
2008
|
|
|
|
|
|
|
|
|
Current
benefit:
|
|
|
|
|
|
|
Federal
|
|
$
|
(325,515
|
)
|
|
$
|
(56,663
|
)
|
State
|
|
|
(50,558
|
)
|
|
|
65,326
|
|
Deferred
benefit
|
|
|
265,411
|
|
|
|
(32,712
|
)
|
|
|
$
|
(110,662
|
)
|
|
$
|
(24,049
|
)
|
The
benefit for income taxes differs from the amount computed by applying the
federal statutory rates for the following reasons:
|
|
Year Ended December 31,
|
|
|
|
2009
|
|
|
2008
|
|
|
|
|
|
|
|
|
Tax
at statutory rate
|
|
$
|
(19,077
|
)
|
|
$
|
338,775
|
|
State
income taxes, net of federal benefit
|
|
|
(3,366
|
)
|
|
|
60,173
|
|
Current
research and development credits
|
|
|
(150,000
|
)
|
|
|
(215,428
|
)
|
Dividends
received deduction
|
|
|
(426
|
)
|
|
|
(24,772
|
)
|
FIN
48 adjustments
|
|
|
-
|
|
|
|
(284,620
|
)
|
Change
in valuation allowance
|
|
|
(43,038
|
)
|
|
|
106,352
|
|
Non-deductible
stock based compensation
|
|
|
42,298
|
|
|
|
34,433
|
|
Other,
net
|
|
|
62,947
|
|
|
|
(38,962
|
)
|
|
|
$
|
(110,662
|
)
|
|
$
|
(24,049
|
)
|
Deferred
tax assets (liabilities) are comprised of the following at December 31, 2009 and
2008:
|
|
2009
|
|
|
2008
|
|
|
|
|
|
|
|
|
Current:
|
|
|
|
|
|
|
Warranty
reserve
|
|
$
|
98,358
|
|
|
$
|
126,691
|
|
Bad
debt allowance
|
|
|
82,306
|
|
|
|
119,766
|
|
Inventory
reserve
|
|
|
237,532
|
|
|
|
261,499
|
|
Uniform
capitalization
|
|
|
83,141
|
|
|
|
185,088
|
|
Accrued
vacation
|
|
|
128,625
|
|
|
|
122,536
|
|
Other
|
|
|
20,972
|
|
|
|
9,303
|
|
Total
current
|
|
|
650,934
|
|
|
|
824,883
|
|
Noncurrent:
|
|
|
|
|
|
|
|
|
Depreciation
|
|
|
184,540
|
|
|
|
499,836
|
|
Intangibles
|
|
|
(263,021
|
)
|
|
|
(206,217
|
)
|
Capital
loss carry forward
|
|
|
343,314
|
|
|
|
426,352
|
|
R&D
credit carry forward
|
|
|
334,105
|
|
|
|
-
|
|
Other
|
|
|
29,989
|
|
|
|
43,456
|
|
Total
|
|
|
628,927
|
|
|
|
763,427
|
|
less
valuation allowance
|
|
|
(63,314
|
)
|
|
|
(106,352
|
)
|
Total
noncurrent
|
|
|
565,613
|
|
|
|
657,075
|
|
|
|
|
|
|
|
|
|
|
Net
deferred tax asset
|
|
$
|
1,216,547
|
|
|
$
|
1,481,958
|
|
At
December 31, 2009 and 2008, the Company had unrecognized tax benefits of
$27,000. For the year ended December 31, 2008, the Company was
no longer subject to U.S. Federal income tax examination on a portion of its
uncertain tax positions and accordingly recorded a tax benefit of $285,000
during the third quarter of 2008. This benefit was partially offset
by a $106,000 valuation allowance which was provided for a portion of the
capital loss carryover from the sale of securities. During the year
ended December 31, 2009 the valuation allowance was reduced by $43,000 as a
result of the ability to utilize a portion of the capital loss carry
forward.
The
Company recognizes accrued interest and penalties related to unrecognized tax
benefits in SG&A expenses. At December 31, 2009, the Company had
accrued $9,000 and $1,000 for the potential payment of interest and penalties,
respectively.
As of
December 31, 2009, the Company is subject to U.S. Federal income tax
examinations for the tax years 2006 through 2009. In addition, the
Company is subject to state and local income tax examinations for the tax years
2004 through 2009, with certain exceptions.
Note
12. Employee Benefit Plans
The
Company maintains a Retirement Savings Plan (the 401(k) Plan) for its employees,
which allows participants to make contributions by salary reduction pursuant to
Section 401(k) of the Internal Revenue Code. Prior to 2008, the
Company’s contributions to the 401(k) Plan were
discretionary. Effective January 1, 2008, the Company modified the
plan to provide that the Company would match 50% of employee contributions, up
to a limit of 6% of employee income. The Company suspended its
matching contribution in May of 2009. No matching contributions were
made between May and December 31, 2009. Employees vest immediately in
their contributions and vest in the Company’s contributions ratably over five
years. The Company made contributions of $68,000 and $195,000 to the
401(k) Plan for the years ended December 31, 2009 and 2008,
respectively.
Note
13. Commitments and Contingencies
The
Company has an agreement with the former owner of Floyd Associates, Inc. to pay
a royalty equal to 5% of the net revenue earned from certain microwave-based
products up to a maximum amount of $1,182,500. The contingent
liability arose as a result of the acquisition of Floyd in 1994. No
minimum payments are required in the agreement. The Company
recognized royalty expense related to this agreement of $5,023 and $3,754 in
2009 and 2008, respectively.
The
Company leases approximately 20,000 sq. ft. of office, engineering, laboratory,
production and warehouse space in Pelham, Alabama, a suburb of Birmingham, under
a lease expiring in November 2010. The Company also leases 500 sq. ft
of office space in Edgewood, Maryland, which can be renewed annually each
April. Rental expense recognized in 2009 and 2008 was $223,545 and
$214,532, respectively. Future minimum rental payments under these
leases are $207,540 and are all due during the 2010 fiscal year.
The
Company places purchase orders with vendors primarily for raw materials,
component parts and other supplies that the Company uses to manufacture its
products. As of December 31, 2009, the Company had approximately
$1,354,000 of open purchase orders.
There are
no material pending legal proceedings other than ordinary, routine litigation
incidental to the business to which the Company is a party or of which any of
its property is subject.
Note
14. Segment Data
The
Company categorizes its operations into two business segments: Laboratory
Products and Air-Monitoring Systems. Operations in these segments
include designing, manufacturing, marketing and selling analytical
instruments. In the Laboratory Products segment, the Company provides
products generally used to ensure regulatory compliance with environmental
requirements for water. Analytical instruments sold in the
Air-Monitoring Systems segment are used for trace level detection of airborne
gaseous chemical warfare agents.
Following
is the Company’s business segment information for 2009 and
2008:
|
|
Laboratory
|
|
|
Air-Monitoring
|
|
|
|
|
|
|
Products
|
|
|
Systems
|
|
|
Total
|
|
2009
|
|
|
|
|
|
|
|
|
|
Revenue
|
|
$
|
14,882,972
|
|
|
$
|
5,028,951
|
|
|
$
|
19,911,923
|
|
Operating
income (loss)
|
|
|
52,471
|
|
|
|
(157,556
|
)
|
|
|
(105,085
|
)
|
Total
Assets
|
|
|
17,088,681
|
|
|
|
3,498,429
|
|
|
|
20,587,110
|
|
Capital
Expenditures
|
|
|
158,604
|
|
|
|
1,729
|
|
|
|
160,333
|
|
Depreciation
and amortization
|
|
|
471,876
|
|
|
|
54,168
|
|
|
|
526,044
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2008
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenue
|
|
$
|
21,836,018
|
|
|
$
|
7,133,082
|
|
|
$
|
28,969,100
|
|
Operating
income (loss)
|
|
|
1,206,756
|
|
|
|
253,354
|
|
|
|
1,460,110
|
|
Total
Assets
|
|
|
17,837,882
|
|
|
|
3,766,459
|
|
|
|
21,604,341
|
|
Capital
Expenditures
|
|
|
305,955
|
|
|
|
42,338
|
|
|
|
348,293
|
|
Depreciation
and amortization
|
|
|
519,448
|
|
|
|
92,771
|
|
|
|
612,219
|
|
Revenues
related to operations in the U.S. and foreign countries for the years ended
December 31, 2009 and 2008 are presented below. Revenues from
external customers are attributed to individual countries based upon locations
to which the product is shipped. Long-lived assets related to
continuing operations in the U.S. and foreign countries as of the years ended
December 31, 2009 and 2008 are as follows:
|
|
Year Ended December 31,
|
|
|
|
2009
|
|
|
2008
|
|
|
|
|
|
|
|
|
Net
revenues from unaffiliated customers:
|
|
|
|
|
|
|
United
States
|
|
$
|
13,079,373
|
|
|
$
|
20,349,455
|
|
Foreign
|
|
$
|
6,832,550
|
|
|
$
|
8,619,645
|
|
|
|
|
|
|
|
|
|
|
Long-lived
assets at end of year:
|
|
|
|
|
|
|
|
|
United
States
|
|
$
|
2,786,526
|
|
|
$
|
3,158,526
|
|
One
customer accounted for approximately 14% of revenues in 2009 and 11% of revenues
in 2008. Sales to federal, state and municipal governments accounted
for 31% of total revenues in 2009 and 27% of total revenues in
2008.
The
following regions had sales in excess of 10% of net revenues: sales to the
Asia-Pacific region were approximately 17% of net revenues in 2009 and 12% for
2008, and sales to the European region were approximately 14% of net revenues
for 2009 and 14% for 2008.
Item
9. Changes in and Disagreements with Accountants on Accounting and
Financial Disclosure
None.
Item 9A(T). Controls and
Procedures
Evaluation
of Disclosure Controls and Procedures
We
maintain disclosure controls and procedures as defined in Rules 13a-15(e) and
15d-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”). Our disclosure controls and procedures are designed to provide reasonable
assurance that information required to be disclosed by the company in the
reports that we file or submit under the Exchange Act is recorded, processed,
summarized and reported within the time periods specified in the rules and forms
of the Securities and Exchange Commission. We performed an evaluation, under the
supervision and participation of our management, including our Chief Executive
Officer/Chief Financial Officer, of the effectiveness of the design and
operation of our disclosure controls and procedures as of the end of the period
covered by this report. Based on this evaluation, our Chief Executive
Officer/Chief Financial Officer concluded that our disclosure controls and
procedures were effective as of the end of the period covered by this
report. We believe that the consolidated financial statements
contained in this report present fairly our financial condition, results of
operations, and cash flows for the fiscal years covered thereby in all material
respects.
Management’s
Report on Internal Control Over Financial Reporting
Management
is responsible for establishing and maintaining an adequate system of internal
control over financial reporting, pursuant to Rule 13a-15(c) of the
Securities Exchange Act, in order to provide reasonable assurance regarding the
reliability of financial reporting and the preparation of financial statements
for external purposes in accordance with accounting principles generally
accepted in the United States (“GAAP”). A company’s internal control over
financial reporting includes policies and procedures that: (i) pertain to
the maintenance of records that, in reasonable detail, accurately and fairly
reflect the transactions and dispositions of the assets of the company,
(ii) provide reasonable assurance that transactions are recorded as
necessary to permit preparation of financial statements in accordance with GAAP,
and that receipts and expenditures of the company are being made only in
accordance with authorizations of management and directors of the company, and
(iii) provide reasonable assurance regarding prevention or timely detection
of unauthorized acquisition, use or disposition of the company’s assets that
could have a material effect on the financial statements.
Because
of its inherent limitations, internal control over financial reporting may not
prevent or detect misstatements. Also, projections of any evaluation of
effectiveness to future periods are subject to the risk that controls may become
inadequate because of changes in conditions, or that the degree of compliance
with the policies or procedures may deteriorate.
In
accordance with the internal control reporting requirements of the Securities
and Exchange Commission, management completed an assessment of the effectiveness
of our internal control over financial reporting as of December 31, 2009.
In making this assessment, management used the criteria set forth in the
Internal Control—Integrated Framework by the Committee of Sponsoring
Organizations of the Treadway Commission (“COSO”). The COSO framework summarizes
each of the components of a company’s internal control system, including:
(i) the control environment, (ii) risk assessment,
(iii) information and communication, and (iv) monitoring
(collectively, the “entity-level controls”), as well as (v) a company’s
control activities (“process-level controls”).
As a
result of the evaluation conducted in 2009, management concluded that our
internal control over financial reporting was effective as of December 31,
2009. This annual report does not include an attestation report of
the Company's registered public accounting firm regarding internal control over
financial reporting. Management's report was not subject to attestation by the
Company's registered public accounting firm pursuant to temporary rules of the
Securities and Exchange Commission that permit the Company to provide only
management's report in this annual report. Accordingly, the Company’s
management's assessment of the effectiveness of our internal control over
financial reporting as of December 31, 2009 has not been audited by our
auditors, McGladrey & Pullen, LLP or any other independent registered
accounting firm.
Item
9B. Other Information
On March
9, 2010, the Compensation Committee revoked its prior Executive Incentive
Compensation Plan and adopted a new plan which is attached hereto as Exhibit
10.17. The new plan applies to Mr. Lancaster, the Company’s CEO & CFO,
only. Dr. Segers, the Company’s President & COO, will be eligible to
receive a performance-based cash bonus for 2010 in an amount to be determined by
the Compensation Committee.
PART
III
Item 10. Directors,
Executive Officers and Corporate Governance
The
information required by this Item is set forth in the sections entitled
“Proposal One: Election of Directors,” “Executive Compensation,” “Compliance
with Section 16(a) of the Securities Exchange Act of 1934” and “Code
of Ethics,” in our Proxy Statement for the 2010 Annual Meeting of Shareholders,
which sections are incorporated in this Annual Report on Form 10-K by
reference.
Item 11. Executive
Compensation
Information
concerning executive compensation is set forth in the section entitled
“Executive Compensation” in our Proxy Statement for the 2010 Annual Meeting of
Shareholders, which section is incorporated in this Annual Report on Form 10-K
by reference.
Item 12. Security
Ownership of Certain Beneficial Owners and Management and Related Stockholder
Matters
Information
for this item is set forth in the sections entitled
“Equity Compensation Plan Information” and “Security Ownership of
Certain Beneficial Owners and Management” in our Proxy Statement for the 2010
Annual Meeting of Shareholders, which sections are incorporated in this Annual
Report on Form 10-K by reference.
Item 13. Certain
Relationships and Related Transactions, and Director Independence
Information
for this item is set forth in the section entitled, “Certain Transactions,
Employment Contracts, Termination of Employment and Change-in-Control
Arrangements” in our Proxy Statement for the 2010 Annual Meeting of
Shareholders, which section is incorporated in this Annual Report on Form 10-K
by reference.
Item 14. Principal
Accountant Fees and Services
Information
for this item is set forth in the section entitled “Principal Accounting Fees
and Services” in our Proxy Statement for the 2010 Annual Meeting of
Shareholders, which section is incorporated in this Annual Report on Form 10-K
by reference.
PART
IV
Item 15. Exhibits and
Financial Statement Schedules
(a)
|
1.
|
Consolidated
Financial Statements of O.I. Corporation and its subsidiary that are
included in Part II, Item 8:
|
|
Page
|
|
|
Report
of Independent Registered Public Accounting Firm
|
16
|
|
|
Consolidated
Balance Sheets at December 31, 2009 and 2008
|
17
|
|
|
Consolidated
Statements of Income for the years ended December 31, 2009 and
2008
|
18
|
|
|
Consolidated
Statements of Cash Flows for the years ended December 31, 2009 and
2008
|
19
|
|
|
Consolidated
Statements of Stockholders' Equity for the years ended December 31, 2009
and 2008
|
20
|
|
|
Notes
to Consolidated Financial Statements
|
21-31
|
|
3.1
|
Articles
of Incorporation of the Company (filed as Exhibit 3.1 to the Company’s
Annual Report on Form 10-K for the year-ended December 31, 2001 and
incorporated herein by reference).
|
|
3.2
|
Amended
and Restated Bylaws of the Company (filed as Exhibit 3.1 to the Company’s
Report on Form 8-K on May 21, 2008 and incorporated herein by
reference).
|
|
*10.1
|
Amended
Employee Stock Purchase Plan (filed as Exhibit 10.2 to the Company’s Form
10-Q for the period ended June 30, 2008 and incorporated herein by
reference).
|
|
*10.2
|
O.I.
Corporation 1993 Incentive Compensation Plan (filed as Exhibit 10.7 to the
Company’s Annual Report on Form 10-K for the year ended December 31, 1993
and incorporated herein by
reference).
|
|
10.3
|
Registration
Rights Agreement among O.I. Corporation and the former shareholders of CMS
Research Corporation dated January 4, 1994 (filed as Exhibit 10.8 to the
Company’s Annual Report on Form 10-K for the year ended December 31, 1994
and incorporated herein by
reference).
|
|
*10.4
|
O.I.
Corporation 2003 Incentive Compensation Plan (filed as Exhibit 99.1 to the
registration statement on Form S-8 (No. 333-106254) and incorporated
herein by reference).
|
|
*10.5
|
Amendment
to the 2003 Incentive Compensation Plan (filed as Exhibit 10.1 to the
Company’s Report on Form 8-K on May 21, 2008 and incorporated herein by
reference).
|
|
*10.6
|
Form
of Nonqualified Stock Option Agreement between O.I. Corporation and its
Directors (filed as Exhibit 10.9 to the Company’s Annual Report on Form
10-K for the year-ended December 31, 2004 and incorporated herein by
reference).
|
|
*10.7
|
Form
of Nonqualified Stock Option Agreement between O.I. Corporation and its
Employees (filed as Exhibit 10.10 to the Company’s Annual Report on Form
10-K for the year-ended December 31, 2004 and incorporated herein by
reference).
|
|
*10.8
|
Form
of Qualified Stock Option Agreement between O.I. Corporation and it
Employees (filed as Exhibit 10.11 to the Company’s Annual Report on Form
10-K for the year-ended December 31, 2004 and incorporated herein by
reference).
|
|
*10.9
|
Employment
Agreement between the Company and J. Bruce Lancaster (filed as Exhibit
10.1 to the Company’s Report on Form 8-K on June 26, 2007 and incorporated
herein by reference).
|
*
|
10.10
|
Amendment
to Employment Agreement between the Company and J. Bruce Lancaster (filed
as Exhibit 10.3 to the Company’s Report on Form 10-Q for the period ending
June 30, 2008 and incorporated herein by
reference).
|
|
|
|
*
|
10.11
|
Employment
Agreement between the Company and Donald P. Segers (filed as Exhibit 10.2
to the Company’s Report on Form 8-K on June 26, 2007 and incorporated
herein by reference).
|
|
|
|
*
|
10.12
|
Amendment
to Employment Agreement between the Company and Donald P. Segers (filed as
Exhibit 10.4 to the Company’s Report on Form 10-Q for the period ending
June 30, 2008 and incorporated herein by
reference).
|
|
|
|
*
|
10.13
|
Executive
Incentive Compensation Plan between O.I. Corporation and its Executive
Officers (as described in the Company’s Report on Form 8-K on November 8,
2007 and incorporated herein by reference).
|
|
|
|
|
10.14
|
Value
Added Reseller Agreement with Agilent Technologies (filed as Exhibit 10.1
to the Company’s Report on Form 10-Q for the period ending June 30, 2008
and incorporated herein by reference). (Portions of this
Exhibit were redacted and filed separately with the Securities and
Exchange Commission pursuant to a Confidential Treatment
Request).
|
|
10.15
|
Amendment
No. 3 to the Value Added Reseller Program Agreement AHA47 By and Between
Agilent Technologies, Inc. and O.I. Corporation dated January 1,
2010. (Portions of this Exhibit have been redacted and filed
separately with the Securities and Exchange Commission pursuant to a
Confidential Treatment Request).
|
|
10.16
|
Agreement
dated August 26, 2009, as amended October 14, 2009, by and between CMS
Field Products, a wholly-owned subsidiary of the Registrant, and Bechtel
National, Inc. (Filed as exhibit 10.1 to the Company’s Report
on Form 10-Q for the period ending September 30, 2009 and incorporated
herein by reference). (Portions of this Exhibit were redacted
and filed separately with the Securities and Exchange Commission pursuant
to a Confidential Treatment Request).
|
|
|
|
*
|
10.17
|
Executive
Incentive Compensation Plan between O.I. Corporation and J. Bruce
Lancaster dated March 9, 2010.
|
|
21.1
|
Subsidiaries
of the Registrant.
|
|
23.1
|
Consent
of Independent Registered Public Accounting
Firm.
|
|
24.1
|
Power
of Attorney (included on signature page to this Form
10-K).
|
|
31.1
|
Principal
Executive Officer and Principal Financial Officer certification pursuant
to 18. U.S.C. Section 1350, as adopted pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002.
|
|
32.1
|
Principal
Executive Officer and Principal Financial Officer certification pursuant
to 18. U.S.C. Section 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002.
|
* Management
contract or compensatory plan or arrangement.
SIGNATURES
Pursuant
to the requirements of Section 13 or 15(d) of the Securities Exchange Act of
1934, registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
|
O.
I. CORPORATION
|
|
|
|
/s/ J. Bruce Lancaster
|
Date:
|
March 15, 2010
|
|
By:
|
J.
Bruce Lancaster
|
|
|
|
Chief
Executive Officer and
|
|
|
|
Chief
Financial Officer
|
|
POWER
OF ATTORNEY
KNOW ALL
PERSONS BY THESE PRESENTS, that each person whose signature appears below
constitutes and appoints J. Bruce Lancaster and Laura Samuelson, and each of
them, acting individually, as his attorney-in-fact, each with full power of
substitution and resubstitution, for him and in his name, place and stead, in
any and all capacities, to sign any and all amendments to this Annual Report on
Form 10-K and other documents in connection herewith and therewith, and to
file the same, with all exhibits thereto, with the Securities and Exchange
Commission, granting unto said attorneys-in-fact and agents, and each of them,
full power and authority to do and perform each and every act and thing
requisite and necessary to be done in connection herewith and therewith and
about the premises, as fully to all intents and purposes as he or she might or
could do in person, hereby ratifying and confirming all that said
attorneys-in-fact and agents, or any of them, or their or his substitute or
substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant
to the requirements of the Securities Exchange Act of 1934, this report has been
signed below by the following persons on behalf of the Registrant and in the
capacities and on the dates indicated:
Signature
|
|
Title
|
|
Date
|
|
|
|
|
|
/s/ J. Bruce Lancaster
|
|
Chief
Executive Officer and Chief Financial Officer
|
|
March 15, 2010
|
J.
Bruce Lancaster
|
|
(Principal
Executive and Principal Financial Officer)
|
|
|
|
|
|
|
|
/s/ Raymond E. Cabillot
|
|
Co-Chairman
of the Board
|
|
March 15, 2010
|
Raymond
E. Cabillot
|
|
|
|
|
|
|
|
|
|
/s/ John K.H. Linnartz
|
|
Co-Chairman
of the Board
|
|
March 15, 2010
|
John
K.H. Linnartz
|
|
|
|
|
|
|
|
|
|
/s/Richard W.K. Chapman
|
|
Director
|
|
March 15, 2010
|
Richard
W.K. Chapman
|
|
|
|
|
|
|
|
|
|
/s/ Donald P. Segers
|
|
President,
Chief Operating Officer and Director
|
|
March 15, 2010
|
Donald
P. Segers
|
|
|
|
|
O. I. Corp. (MM) (NASDAQ:OICO)
Historical Stock Chart
From Oct 2024 to Nov 2024
O. I. Corp. (MM) (NASDAQ:OICO)
Historical Stock Chart
From Nov 2023 to Nov 2024